Lineage Cell Therapeutics (LCTX) 10-Q 9 May 19 2019 Q1 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	3 Months Ended
	Mar. 31, 2019	May 06, 2019
LifeMap Solutions, Inc [Member]
Entity Registrant Name	BIOTIME INC
Entity Central Index Key	0000876343
Document Type	10-Q
Document Period End Date	Mar. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	false
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		149,642,861
Trading Symbol	BTX
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2019

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands		Mar. 31, 2019	Dec. 31, 2018
CURRENT ASSETS
Cash and cash equivalents		$ 18,011	$ 23,587
Marketable equity securities		9,085	7,154
Trade accounts and grants receivable, net		1,402	767
Receivables from affiliates, net (Note 10)			2,112
Landlord receivable			840
Prepaid expenses and other current assets		2,158	1,898
Total current assets		30,656	36,358
NONCURRENT ASSETS
Property and equipment, net		8,918	5,835
Deposits and other long-term assets		890	505
Promissory note from Juvenescence (Note 5)		22,482	22,104
Goodwill	[1]	12,977
Intangible assets, net		49,829	3,125
TOTAL ASSETS		183,715	101,660
CURRENT LIABILITIES
Accounts payable and accrued liabilities		7,336	6,463
Financing lease and right of use lease liabilities, current portion		954	237
Promissory notes, current portion		18	70
Deferred grant revenue		43	42
Liability classified warrants, current portion		372
Total current liabilities		8,723	6,812
LONG-TERM LIABILITIES
Deferred tax liability		8,581
Deferred revenues, net of current portion		200
Deferred rent liabilities, net of current portion			244
Right-of-use lease liability, net of current portion		4,016	1,854
Financing lease, net of current portion		103	104
Liability classified warrants, net of current portion, and other long-term liabilities		856	400
TOTAL LIABILITIES		22,479	9,414
Commitments and contingencies (Note 15)
SHAREHOLDERS' EQUITY
Preferred shares, no par value, authorized 2,000 shares; none issued and outstanding as of March 31, 2019 and December 31, 2018
Common shares, no par value, 250,000 shares authorized; 149,388 shares issued and outstanding as of March 31, 2019 and 127,136 shares issued and outstanding as of December 31, 2018		384,553	354,270
Accumulated other comprehensive income		694	1,426
Accumulated deficit		(222,403)	(261,856)
BioTime, Inc. shareholders' equity		162,844	93,840
Noncontrolling interest (deficit)		(1,608)	(1,594)
Total shareholders' equity		161,236	92,246
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY		183,715	101,660
OncoCyte Corporation [Member]
NONCURRENT ASSETS
Equity method investment		57,963	20,250
SHAREHOLDERS' EQUITY
Common shares, no par value, 250,000 shares authorized; 149,388 shares issued and outstanding as of March 31, 2019 and 127,136 shares issued and outstanding as of December 31, 2018		58,000
Asterias Biotherapeutics [Member]
NONCURRENT ASSETS
Equity method investment			$ 13,483
[1]	Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger (see Note 3).

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Mar. 31, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, no par value
Preferred stock, shares authorized	2,000,000	2,000,000
Preferred stock, shares issued
Preferred stock, shares outstanding
Common stock, no par value
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	149,388,000	127,136,000
Common stock, shares outstanding	149,388,000	127,136,000

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
REVENUES:
Grant revenue	$ 749	$ 326
Royalties from product sales and license fees	86	136
Subscription and advertisement revenues		239
Sale of research products and services	93
Total revenues	928	701
Cost of sales	(68)	(109)
Gross profit	860	592
OPERATING EXPENSES:
Research and development	4,961	5,935
Acquired in-process research and development		800
General and administrative	8,660	6,044
Total operating expenses	13,621	12,779
Loss from operations	(12,761)	(12,187)
OTHER INCOME/(EXPENSES):
Interest income, net	442	52
Gain on sale of equity method investment in Ascendance		3,215
Unrealized gain on marketable equity securities	1,931	215
Unrealized gain on warrant liability	37
Other income (expense), net	806	(176)
Total other income (expense), net	47,673	(51,511)
INCOME/(LOSS) BEFORE INCOME TAXES	34,912	(63,698)
Deferred income tax benefit (Note 13)	4,384
NET INCOME/(LOSS)	39,296	(63,698)
Net loss attributable to noncontrolling interest	14	150
NET INCOME/(LOSS) ATTRIBUTABLE TO BIOTIME, INC.	$ 39,310	$ (63,548)
NET INCOME/(LOSS) PER COMMON SHARE:
BASIC	$ 0.3	$ (0.5)
DILUTED	$ 0.3	$ (0.5)
WEIGHTED AVERAGE NUMBER OF SHARES OF COMMON STOCK OUTSTANDING:
BASIC	132,865,000	126,869,000
DILUTED	132,869,000	126,869,000
OncoCyte Corporation [Member]
OTHER INCOME/(EXPENSES):
Gain (loss) on equity method investment	$ 37,713	$ (37,419)
Asterias Biotherapeutics [Member]
OTHER INCOME/(EXPENSES):
Gain (loss) on equity method investment	$ 6,744	$ (17,398)

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income/(Loss) (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
NET INCOME/(LOSS)	$ 39,296	$ (63,698)
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment, net of tax	(732)	75
Available-for-sale investments:
Reclassification of beginning accumulated other comprehensive income to accumulated deficit		(328)
COMPREHENSIVE INCOME/(LOSS)	38,564	(63,951)
Less: Comprehensive loss attributable to noncontrolling interest	14	150
COMPREHENSIVE INCOME/(LOSS) ATTRIBUTABLE TO BIOTIME, INC. COMMON SHAREHOLDERS	$ 38,578	$ (63,801)

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income/(loss) attributable to BioTime, Inc.	$ 39,310	$ (63,548)
Net loss allocable to noncontrolling interest	(14)	(150)
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Gain on sale of equity method investment in Ascendance		(3,215)
Acquired in-process research and development		800
Unrealized gain on marketable equity securities	(1,931)	(215)
Deferred income tax benefit	(4,384)
Depreciation expense, including amortization of leasehold improvements	269	281
Amortization of right-of-use asset	14
Amortization of intangible assets	485	582
Stock-based compensation	1,440	984
Change in fair value of liability classified warrants	(37)	108
Foreign currency remeasurement and other (gain) loss	(839)	87
Changes in operating assets and liabilities:
Accounts and grants receivable, net	(614)	(37)
Receivables from affiliates, net of payables	2,129	175
Prepaid expenses and other current assets	(66)	(213)
Accounts payable and accrued liabilities	(241)	(840)
Deferred revenue and other liabilities	(378)	46
Net cash used in operating activities	(9,314)	(10,338)
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from the sale of equity method investment in Ascendance		3,215
Purchase of in-process research and development		(800)
Cash and cash equivalents acquired in the Asterias Merger	3,117
Purchase of equipment and other assets	(169)	(198)
Security deposit paid and other	(2)	(6)
Net cash provided by investing activities	2,946	2,211
CASH FLOWS FROM FINANCING ACTIVITIES:
Common shares received and retired for employee taxes paid	(74)	(7)
Reimbursement from landlord on tenant improvements	738
Repayment of principal portion of promissory notes	(52)
Proceeds from sale of subsidiary warrants		737
Repayment of financing lease liabilities	(6)	(97)
Net cash provided by financing activities	606	633
Effect of exchange rate changes on cash, cash equivalents and restricted cash	53	60
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(5,709)	(7,434)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH: At beginning of the period	24,399	37,685
CASH, CASH EQUIVALENTS AND RESTRICTED CASH: At end of the period	18,690	30,251
OncoCyte Corporation [Member]
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Unrealized (gain) loss on equity method investment	(37,713)	37,419
Asterias Biotherapeutics [Member]
Adjustments to reconcile net income (loss) attributable to BioTime, Inc. to net cash used in operating activities:
Unrealized (gain) loss on equity method investment	$ (6,744)	$ 17,398

Organization and Business Overv

Organization and Business Overview	3 Months Ended
	Mar. 31, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Business Overview	1. Organization and Business Overview BioTime is a clinical-stage biotechnology company developing new cellular therapies for degenerative retinal diseases, neurological conditions associated with demyelination, and aiding the body in detecting and combating cancer. BioTime’s programs are based on its proprietary cell-based therapy platform and associated development and manufacturing capabilities. With this platform BioTime develops and manufactures specialized, terminally-differentiated human cells from its pluripotent and progenitor cell starting materials. These differentiated cells are developed either to replace or support cells that are dysfunctional or absent due to degenerative disease or traumatic injury, or administered as a means of helping the body mount an effective immune response to cancer. BioTime has three cell therapy programs in clinical development: ● OpRegen ® ● OPC1 ● VAC2 BioTime also has cell/drug delivery programs that are based upon its proprietary HyStem ® HyStem ® BioTime is also enabling early-stage programs in other new technologies through its own research programs as well as through other subsidiaries, affiliates or investees. Asterias Merger On November 7, 2018, BioTime, Asterias and Patrick Merger Sub, Inc., a wholly owned subsidiary of BioTime (“Merger Sub”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) whereby BioTime agreed to acquire all of the outstanding common stock of Asterias in a stock-for-stock transaction (the “Asterias Merger”). On March 7, 2019, the shareholders of each of BioTime and Asterias approved the Merger Agreement. Prior to the consummation of the Merger Agreement, BioTime owned approximately 38% of Asterias’ issued and outstanding common stock and accounted for Asterias as an equity method investment. On March 8, 2019, the Asterias merger closed with Asterias surviving as a wholly-owned subsidiary of BioTime. The former stockholders of Asterias (other than BioTime) received 0.71 shares of BioTime common stock for every share of Asterias common stock they owned. BioTime issued 24,695,898 shares of common stock, including 58,085 shares issued in respect of restricted stock units issued by Asterias that immediately vested in connection with the closing of the Asterias Merger. The aggregate dollar value of such shares, based on the closing price of BioTime common stock on March 8, 2019, was $32.4 million. BioTime also assumed warrants to purchase shares of Asterias common stock. The Asterias Merger has been accounted for using the acquisition method of accounting in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations See Note 3 for a full discussion of the Asterias Merger. Investment in OncoCyte BioTime has significant equity holdings in OncoCyte Corporation (“OncoCyte”), a publicly traded company, which BioTime founded and, in the past, was a majority-owned consolidated subsidiary. OncoCyte (NYSE American: OCX) is developing confirmatory diagnostic tests for lung cancer utilizing novel liquid biopsy technology. As of March 31, 2019, BioTime owned 14.7 million shares of OncoCyte common stock, or 28% of its outstanding shares.

Basis of Presentation, Liquidit

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Basis of Presentation, Liquidity and Summary of Significant Accounting Policies	2. Basis of Presentation, Liquidity and Summary of Significant Accounting Policies The unaudited condensed consolidated interim financial statements presented herein, and discussed below, have been prepared in accordance with GAAP for interim financial information and with the instructions to Form 10-Q and Article 8 of Regulation S-X. In accordance with those rules and regulations certain information and footnote disclosures normally included in comprehensive consolidated financial statements have been condensed or omitted. The condensed consolidated balance sheet as of December 31, 2018 was derived from the audited consolidated financial statements at that date, but does not include all the information and footnotes required by GAAP. These condensed consolidated interim financial statements should be read in conjunction with the audited consolidated financial statements and notes thereto included in BioTime’s Annual Report on Form 10-K for the year ended December 31, 2018. The accompanying condensed consolidated interim financial statements, in the opinion of management, include all adjustments, consisting only of normal recurring adjustments, necessary for a fair presentation of BioTime’s financial condition and results of operations. The condensed consolidated results of operations are not necessarily indicative of the results to be expected for any other interim period or for the entire year. Principles of consolidation BioTime’s condensed consolidated interim financial statements include the accounts of its subsidiaries. The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of March 31, 2019. Subsidiary Field of Business BioTime Ownership Country Asterias BioTherapeutics, Inc. Cell therapy clinical development programs in spinal cord injury and oncology 100% USA Cell Cure Neurosciences Ltd. (“Cell Cure”) Products to treat age-related macular degeneration 99% (1) Israel ES Cell International Pte. Ltd. (“ESI”) Stem cell products for research, including clinical grade cell lines produced under cGMP 100% Singapore OrthoCyte Corporation (“OrthoCyte”) Developing bone grafting products for orthopedic diseases and injuries 99.8% USA (1) Includes shares owned by BioTime and ESI. For the three months ended March 31, 2018, BioTime’s unaudited consolidated results include AgeX’s consolidated results for the full period presented. As a result of the AgeX Deconsolidation, beginning on August 30, 2018 (a) AgeX’s consolidated financial statements and consolidated results are no longer a part of BioTime’s condensed consolidated interim financial statements and results, and (b) the fair value of AgeX common stock held by BioTime is now reflected on BioTime’s condensed consolidated balance sheet and the changes in the fair value of those shares during the applicable reporting period are reflected as gains or losses in BioTime’s condensed consolidated statements of operations included in other income and expenses, net. All material intercompany accounts and transactions have been eliminated in consolidation. As of March 31, 2019, BioTime consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholders’ equity on BioTime’s consolidated balance sheets. Liquidity Since inception, BioTime has incurred significant operating losses and has funded its operations primarily through the issuance of equity securities, sale of common stock of AgeX, a former subsidiary, receipt of research grants, royalties from product sales, license revenues and sales of research products. At March 31, 2019, BioTime had an accumulated deficit of approximately $222.4 million, working capital of $21.9 million and shareholders’ equity of $161.2 million. BioTime has evaluated its projected cash flows and believes that its $27.1 million of cash, cash equivalents and marketable equity securities at March 31, 2019, plus the value of its equity investment in OncoCyte ($58.0 million based on the closing price of OncoCyte common stock on March 31, 2019), provide sufficient cash, cash equivalents, and liquidity to carry out BioTime’s current planned operations through at least twelve months from the issuance date of the consolidated financial statements included herein. Although BioTime has no plans to liquidate its investment in OncoCyte, if BioTime needs near term working capital or liquidity to supplement its cash and cash equivalents for its operations, BioTime may sell some, or all, of its OncoCyte shares, as necessary. The AgeX Distribution was completed on November 28, 2018 when AgeX became a publicly traded company (see Note 6). BioTime continues to hold a minority interest in AgeX that may be a source of additional liquidity to BioTime as a marketable equity security. If the promissory note issued by Juvenescence in favor of BioTime discussed in Note 5 is converted into shares of Juvenescence common stock prior to its maturity date, the Juvenescence common stock may be a marketable security that BioTime may use to supplement its liquidity, as needed. If such promissory note is not converted, it is payable in cash, plus accrued interest, at maturity on August 30, 2020. On March 8, 2019, with the consummation of the Asterias Merger, Asterias became BioTime’s wholly-owned subsidiary. BioTime began consolidating Asterias’ operations and results with its operations and results beginning on March 8, 2019 (see Note 3). As BioTime integrates Asterias’ operations into its own, BioTime expects to make extensive reductions in headcount and to reduce non-clinical related spend, in each case, as compared to Asterias’ operations before the Asterias Merger. BioTime’s projected cash flows are subject to various risks and uncertainties, and the unavailability or inadequacy of financing to meet future capital needs could force BioTime to modify, curtail, delay, or suspend some or all aspects of its planned operations. BioTime’s determination as to when it will seek new financing and the amount of financing that it will need will be based on BioTime’s evaluation of the progress it makes in its research and development programs, any changes to the scope and focus of those programs, any changes in grant funding for certain of those programs, and projection of future costs, revenues, and rates of expenditure. BioTime may be required to delay, postpone, or cancel clinical trials or limit the number of clinical trial sites, unless it is able to obtain adequate financing. In addition, BioTime BioTime cannot assure that adequate financing will be available on favorable terms, if at all. Sales of additional equity securities by BioTime or its subsidiaries and affiliates could result in the dilution of the interests of current shareholders. Business Combinations BioTime accounts for business combinations, such as the Asterias Merger completed in March 2019, in accordance with ASC Topic 805, which requires the purchase price to be measured at fair value. When the purchase consideration consists entirely of shares of BioTime’s common stock, BioTime calculates the purchase price by determining the fair value, as of the acquisition date, of shares issued in connection with the closing of the acquisition. BioTime recognizes estimated fair values of the tangible assets and intangible assets acquired, including in-process research and development (“IPR&D”), and liabilities assumed as of the acquisition date, and records as goodwill any amount of the fair value of the tangible and intangible assets acquired and liabilities assumed in excess of the purchase price. Equity method investments at fair value BioTime uses the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance with GAAP, over the operating and financial policies of a company. For equity method investments which BioTime has elected to measure at fair value, unrealized gains and losses are reported in the consolidated statements of operations in other income and expenses, net. As further discussed in Note 4, BioTime has elected to account for its OncoCyte shares at fair value using the equity method of accounting because beginning on February 17, 2017, the respective date on which BioTime deconsolidated OncoCyte, BioTime has not had control of OncoCyte, as defined by GAAP, but continues to exercise significant influence over this company. Under the fair value method, BioTime’s value in shares of common stock it holds in OncoCyte is marked to market at each balance sheet date using the closing price of OncoCyte common stock on the NYSE American multiplied by the number of shares of OncoCyte held by BioTime, with changes in the fair value of the OncoCyte shares included in other income and expenses, net, in the consolidated statements of operations. The OncoCyte shares are considered level 1 assets as defined by ASC 820, Fair Value Measurements and Disclosures Prior to the Asterias Merger completed on March 8, 2019 discussed in Note 3, BioTime accounted for its Asterias shares held at fair value, using the equity method of accounting. Revenue Recognition During the first quarter of 2018, BioTime adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASU 2014-09, Revenues from Contracts with Customers (Topic 606) BioTime recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it is entitled to receive in exchange for such product or service. In doing so, BioTime follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. BioTime considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. BioTime applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. BioTime’s largest source of revenue is currently related to government grants. In applying the provisions of ASU 2014-09, BioTime has determined that government grants are out of the scope of ASU 2014-09 because the government entities do not meet the definition of a “customer”, as defined by ASU 2014-09, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. BioTime has, and will continue to, account for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements Deferred grant revenues represent grant funds received from the governmental funding agencies for which the allowable expenses have not yet been incurred as of the balance sheet date reported. As of March 31, 2019, deferred grant revenue was immaterial. Basic and diluted net income (loss) per share attributable to common shareholders Basic earnings per share is calculated by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by BioTime, if any, during the period. Diluted earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common shares issuable under outstanding stock options and warrants, using the treasury-stock method, convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any. For the three months ended March 31, 2019, BioTime reported net income attributable to common shareholders, and therefore, did an analysis of common share equivalents to determine their impact on diluted net income, if any. For the three months ended March 31, 2018, The following weighted average common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Stock options 14,628 9,243 Warrants (1) - 9,395 BioTime Warrants (2) 533 - Restricted stock units 278 56 (1) The warrants expired on October 1, 2018. (2) Although the BioTime warrants are classified as liabilities, these warrants are considered for dilutive earnings per share calculations in accordance with ASC 260, Earnings Per Share Lease accounting and impact of adoption of the new lease standard On January 1, 2019, BioTime adopted ASU 2016-02, Leases Codification Improvements to Topic 842, Leases, Leases (Topic 842): Targeted improvements, BioTime management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, BioTime continues to use (i) greater to or equal to 75% to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) greater to or equal to 90% to determine whether the present value of the sum of lease payments is substantially the fair value of the underlying asset. Under the available practical expedients, BioTime accounts for the lease and non-lease components as a single lease component. BioTime recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the condensed consolidated balance sheet. ROU assets represent BioTime’s right to use an underlying asset during the lease term and lease liabilities represent BioTime’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of BioTime’s leases do not provide an implicit rate, BioTime uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. BioTime uses the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. BioTime’s lease terms may include options to extend or terminate the lease when it is reasonably certain that BioTime will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases are included as right-of-use assets in property and equipment (see Note 15), and ROU lease liabilities, current and long-term, in the condensed consolidated balance sheets. Financing leases are included in property and equipment, and in financing lease liabilities, current and long-term, in BioTime’s condensed consolidated balance sheets. In connection with the adoption on ASC 842 on January 1, 2019, BioTime derecognized net book value of leasehold improvements and corresponding lease liabilities of $1.9 million and $2.0 million, respectively, which was the carrying value of certain operating leases as of December 31, 2018, included in property and equipment and lease liabilities, respectively, recorded pursuant to build to suit lease accounting under the previous ASC 840 lease standard. The derecognition of these amounts from the superseded ASC 840 lease standard was offset by a cumulative effect adjustment of $0.1 million as a reduction of BioTime’s accumulated deficit on January 1, 2019. These build to suit leases were primarily related to the Alameda and the Cell Cure Leases described in Note 15. ASC 842 requires build to suit leases recognized on BioTime’s consolidated balance sheets as of December 31, 2018 to be derecognized upon the adoption of the new lease standard and be recognized in accordance with the new standard on January 1, 2019. The adoption of ASC 842 had a material impact in BioTime’s consolidated balance sheets, with the most significant impact resulting from the recognition of ROU assets and lease liabilities for operating leases with remaining terms greater than twelve months on the adoption date (see Note 15). BioTime’s accounting for financing leases (previously referred to as “capital leases”) remained substantially unchanged. Other recently adopted accounting pronouncements Adoption of ASU 2016-18 , Statement of Cash Flows (Topic 230) Statement of Cash Flows (Topic 230): Restricted Cash The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheet dates that comprise the total of the same such amounts shown in the condensed consolidated statements of cash flows for all periods presented herein and effected by the adoption of ASU 2016-18 (in thousands): March 31, 2019 December 31, 2018 March 31, 2018 December 31, 2017 (unaudited) (unaudited) Cash and cash equivalents $ 18,011 $ 23,587 $ 29,827 $ 36,838 Restricted cash included in prepaid expenses and other current assets (see Note 15) - 346 346 - Restricted cash included in deposits and other long-term assets (see Note 15) 679 466 78 847 Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows $ 18,690 $ 24,399 $ 30,251 $ 37,685 Adoption of ASU 2016-01, Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities Changes to the current GAAP model under ASU 2016-01 primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, ASU 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. marketable equity securities policy, BioTime adopted ASU 2016-01 on January 1, 2018. Adoption of ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting - Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Recently Issued Accounting Pronouncements Not Yet Adopted In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement

Asterias Merger

Asterias Merger	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Asterias Merger	3. Asterias Merger On March 8, 2019, the Asterias Merger closed with Asterias surviving as a wholly-owned subsidiary of BioTime. The former stockholders of Asterias (other than BioTime) received 0.71 shares of BioTime common stock (the “Merger Consideration”) for every share of Asterias common stock they owned (the “Merger Exchange Ratio”). BioTime issued 24,695,898 shares of common stock, including 58,085 shares issued in respect of restricted stock units issued by Asterias that immediately vested in connection with the closing of the Asterias Merger. The fair value of such shares, based on the closing price of BioTime common stock on March 8, 2019, was $32.4 million. In connection with the closing of the Asterias Merger, BioTime assumed outstanding warrants to purchase shares of Asterias common stock, as further discussed below and in Note 11, and assumed sponsorship of the Asterias 2013 Equity Incentive Plan (see Note 12). All stock options to purchase shares of Asterias common stock outstanding immediately prior to the closing of the Asterias Merger were canceled at the closing for no consideration. As of March 31, 2019, the assets and liabilities of Asterias have been included in the condensed consolidated balance sheet of BioTime. The results of operations of Asterias from March 8, 2019 through March 31, 2019 have been included in the condensed consolidated statement of operations of BioTime for the three months ended March 31, 2019. Calculation of the purchase price The calculation of the purchase price for the Asterias Merger and the Merger Consideration transferred on March 8, 2019 was as follows (in thousands, except for share and per share amounts): BioTime (38% ownership interest) Shareholders other than BioTime (approximate 62% ownership interest) Total Outstanding Asterias common stock as of March 8, 2019 21,747,569 34,783,333 (1) 56,530,902 (1) Exchange ratio 0.710 0.710 0.710 BioTime common stock issuable 15,440,774 (2) 24,695,898 (3) 40,136,672 Per share price of BioTime common stock as of March 8, 2019 $ 1.31 $ 1.31 $ 1.31 Purchase price (in $000s) $ 20,227 (2) $ 32,353 $ 52,580 (1) Includes 81,810 shares of Asterias restricted stock unit awards that immediately vested on March 8, 2019 and converted into the right to receive shares of BioTime common stock based on the Merger Exchange Ratio, resulting in 58,085 shares of BioTime common stock issued on March 8, 2019 as part of the Merger Consideration. These restricted stock units were principally attributable to pre-combination services and included as part of the purchase price in accordance with ASC 805 . See Note 12 for Asterias restricted stock units that vested on the closing of the Asterias Merger attributable to post-combination services that were recorded outside of the purchase price as an immediate charge to stock-based compensation expense. (2) Estimated fair value for BioTime’s previously held 38% ownership interest in Asterias common stock is part of the total purchase price of Asterias for purposes of the purchase price allocation under ASC 805 and for BioTime’s adjustment of its 38% interest to fair value at the effective date of the Asterias Merger and immediately preceding the consolidation of Asterias’ results with BioTime. No actual shares of BioTime common stock were issued to BioTime in connection with the Asterias Merger. (3) Net of a de minimis number of fractional shares which were paid in cash. Estimated purchase price allocation BioTime allocated the acquisition consideration to tangible and identifiable intangible assets acquired and liabilities assumed based on their estimated fair values as of the acquisition date. The fair value of the acquired tangible and identifiable intangible assets were determined based on inputs that are unobservable and significant to the overall fair value measurement. It is also based on estimates and assumptions made by management at the time of the acquisition. As such, this was classified as Level 3 fair value hierarchy measurements and disclosures. The Merger Consideration allocation below is preliminary and as additional information becomes available, BioTime may further revise the preliminary acquisition consideration allocation. BioTime expects to finalize the acquisition consideration allocation by the end of 2019. Any such revisions or changes may be material. The following table sets forth a preliminary allocation of the purchase price to Asterias’ tangible and identifiable intangible assets acquired and liabilities assumed on the closing of the Asterias Merger, with the excess recorded as goodwill (in thousands): Assets acquired: Cash and cash equivalents $ 3,117 Prepaid expenses and other assets, current and noncurrent 660 Machinery and equipment 369 Long-lived intangible assets - royalty contracts 650 Acquired in-process research and development (“IPR&D”) 46,540 Total assets acquired 51,336 Liabilities assumed: Accrued liabilities and accounts payable 1,136 Liability classified warrants 867 Deferred license revenue 200 Long-term deferred income tax liability 12,965 Total liabilities assumed 15,168 Net assets acquired, excluding goodwill (a) 36,168 Fair value of BioTime common stock held by Asterias (b) 3,435 Total purchase price (c) 52,580 Estimated goodwill (c-a-b) $ 12,977 The valuation of identifiable intangible assets and their estimated useful lives are as follows (in thousands, except for useful life): ​ Preliminary Estimated Asset Fair Value Useful Life (Years) In process research and development (“IPR&D”) $ 46,540 n/a Royalty contracts 650 5 $ 47,190 The following is a discussion of the valuation methods used to determine the fair value of Asterias’ significant assets and liabilities in connection with the Asterias Merger: Acquired In-Process Research and Development (“ IPR&D”) and Deferred Income Tax Liability BioTime determined that the estimated aggregate fair value of the AST-Clinical programs was $46.5 million as of the acquisition date using a probability weighted discounted cash flow method for each respective program. This approach estimates the probability of the AST-Clinical Programs achieving successful completion of remaining clinical trials and related approvals into the valuation technique. To calculate fair value of the AST-Clinical programs under the discounted cash flow method, BioTime used probability-weighted, projected cash flows discounted at a rate considered appropriate given the significant inherent risks associated with cell therapy development by clinical-stage companies. Cash flows were calculated based on estimated projections of revenues and expenses related to each respective program. Cash flows were assumed to extend through a seven-year market exclusivity period for the AST-OPC1 program from the date of market launch. Revenues from commercialization of the AST-Clinical Programs were based on estimated market potential for the indication of each program. The resultant cash flows were then discounted to present value using a weighted-average cost of capital for companies with profiles substantially similar to that of BioTime, which BioTime believes represents the rate that market participants would use to value the assets. BioTime compensated for the phase of development of the program by applying a probability factor to its estimation of the expected future cash flows. The projected cash flows were based on significant assumptions, including the indications in which BioTime will pursue development of the AST-Clinical programs, the time and resources needed to complete the development and regulatory approval, estimates of revenue and operating profit related to the program considering its stage of development, the life of the potential commercialized product, market penetration and competition, and risks associated with achieving commercialization, including delay or failure to obtain regulatory approvals to conduct clinical studies, failure of clinical studies, delay or failure to obtain required market clearances, and intellectual property litigation. These IPR&D assets are indefinite-lived intangible assets until the completion or abandonment of the associated research and development (“R&D”) efforts. Once the R&D efforts are completed or abandoned, the IPR&D will either be amortized over the asset life as a finite-lived intangible asset or be impaired, respectively, in accordance with ASC 350, Intangibles – Goodwill and Other Because the IPR&D (prior to completion or abandonment of the R&D) is considered an indefinite-lived asset for accounting purposes, the fair value of the IPR&D on the acquisition date creates a deferred income tax liability (“DTL”) in accordance with ASC 740, Income Taxes Royalty contracts Deferred license revenue – and Novo Nordisk A/S (“Novo Nordisk”) entered into an option for Novo Nordisk or its designated U.S. affiliate to license, on a non-exclusive basis, certain intellectual property related to culturing pluripotent stem cells, such as hES cells, in suspension. Under the terms of the option, Asterias received a one-time upfront payment of $1.0 million, in exchange for a 24-month period option to negotiate a non-exclusive license during which time Asterias has agreed to not grant any exclusive licenses inconsistent with the Novo Nordisk option. This option is considered a performance obligation as it provides Novo Nordisk with a material right that it would not receive without entering into the contract. For business combination purposes under ASC 805, the fair value of this performance obligation to BioTime, from a market participant perspective, is the estimated costs BioTime may incur, plus a normal profit margin for the level of effort required to perform under the contract after the acquisition date, assuming Novo Nordisk exercised its option, including, but not limited to, negotiation costs, legal fees, arbitration, if any, and other related costs. Management has estimated those costs, plus a normal profit margin, to be approximately $200,000 in the estimated purchase price allocation. Liability classified warrants – The fair value of the Asterias Warrants was determined by using Black-Scholes option pricing models which take into consideration the probability of the fundamental transaction, which for purposes of the above valuation was assumed to be at 100% and net cash settlement occurring, using the contractual remaining term of the warrants. In applying these models, these inputs included key assumptions including the per share closing price of BioTime common stock on March 8, 2019, volatility computed in accordance with the provisions of the Warrant Agreement and, to a large extent, assumptions based on discussions with a majority of the holders of the Asterias Warrants since the closing of the Asterias Merger to settle the Asterias Warrants in cash or in shares of BioTime common stock. Based on such discussions, BioTime believes the fair value of the Asterias Warrants as of the closing of the Asterias Merger is not subject to change significantly, however, to the extent any Asterias Warrants that were not settled in cash or in BioTime common stock discussed below, were automatically converted to BioTime warrants 30 days after the closing of the Asterias Merger. In April 2019, Asterias Warrants representing approximately $372,000 in fair value were settled: $332,000 in fair value was settled in exchange for 251,835 shares of BioTime common stock, and $40,000 in fair value was settled in exchange for cash. The Asterias Warrants settled in exchange for shares of BioTime common stock were held by Broadwood Partners, L.P., an Asterias and BioTime shareholder. The Asterias Warrants settled in exchange for cash were held by other parties. The remaining Asterias Warrants (representing approximately $495,000 in fair value as of March 31, 2019) were converted into warrants to purchase shares of BioTime common stock using the Merger Exchange Ratio (the “BioTime Warrants”). As of March 31, 2019, the total number of shares of BioTime common stock subject to warrants that were assumed by BioTime in connection with the Asterias Merger was 1,997,342, of which 907,442 were settled in April 2019 discussed above and 1,089,900 were converted to BioTime Warrants 30 days after the closing of the Asterias Merger, with similar terms and conditions retained under the BioTime Warrants as per the original Warrant Agreements. The BioTime Warrants have an exercise price of $6.15 per warrant share and expire on May 13, 2021. BioTime is accounting for the outstanding BioTime Warrants as a liability at fair value, with subsequent changes to the fair value of the BioTime Warrants at each reporting period thereafter included in the consolidated statement of operations. Fair value of BioTime common stock held by Asterias Goodwill – G Depending on the structure of a particular acquisition, goodwill and identifiable intangible assets may not be deductible for tax purposes. Goodwill recorded in the Asterias Merger is not expected to be deductible for tax purposes (see Note 13). During the three months ended March 31, 2019, BioTime incurred $3.5 million in acquisition related costs which were recorded in general and administrative expenses in the accompanying condensed consolidated statements of operations. Unaudited Supplemental Pro Forma Information The unaudited supplemental pro forma financial information presented below is for illustrative purposes only and is not necessarily indicative of the financial operations or results of operations that would have been realized if the Asterias Merger had been completed on the date indicated, does not reflect synergies that might have been achieved, nor is it indicative of future operating results or financial position. The pro forma adjustments are based upon currently available information and certain assumptions BioTime believes are reasonable under the circumstances. The following unaudited supplemental pro forma financial information summarizes the consolidated results of operations for the periods presented, as if the Asterias Merger was completed on January 1, 2018. The unaudited supplemental pro forma information reports actual operating results, adjusted to include the pro forma effect of certain fair value adjustments for acquired items, such as the amortization of identifiable, long-lived intangible assets, depreciation of machinery and equipment, and the related tax effects of the acquisition. It also includes pro forma adjustments to certain items related to the Asterias Merger that were reported separately in each of BioTime and Asterias' respective statements of operations prior to the Asterias Merger, such as gains and losses reported by BioTime for its 38% ownership interest in Asterias, and gains and losses reported by Asterias for its ownership of BioTime shares held as marketable equity securities. The unaudited supplemental pro forma financial information for the periods presented is as follows (in thousands, except per share data): Three months ended March 31 ​ 2019 2018 Pro forma net revenue $ 877 $ 974 Pro forma operating expenses (15,368) (17,430) Pro forma loss from operations (14,491) (16,456) Pro forma other income (loss), net 40,537 (33,137) Pro forma net income (loss) attributable to BioTime shareholders 26,039 (45,038) Pro forma net income/(loss) per share, basic and diluted $ 0.20 $ (0.30) Prior to the Asterias Merger being consummated in March 2019, BioTime elected to account for its 21.7 million shares of Asterias common stock March 8, 2019, the closing date of the Asterias Merger, based on $0.93 per share, which was calculated by multiplying (a) $1.31, $13.5 March 31, 2018 March 31, 2018 All share prices were determined based on the closing price of BioTime or Asterias common stock on the NYSE American on the applicable dates. Asterias Merger Related Litigation –

Equity Method of Accounting for

Equity Method of Accounting for Common Stock of Oncocyte, at Fair Value	3 Months Ended
	Mar. 31, 2019
Deconsolidation Of Subsidiaries
Equity Method of Accounting for Common Stock of Oncocyte, at Fair Value	4. Equity Method Accounting for Common Stock of OncoCyte, at Fair Value BioTime elected to account for its 14.7 million shares of OncoCyte common stock 20.3 million as of December 31, 2018 1.38 For the three months ended March 31, 2019, BioTime recorded an unrealized gain of $37.7 million due to the increase in OncoCyte’s stock price from December 31, 2018 to March 31 For the three months ended , BioTime recorded an unrealized . All share prices are determined based on OncoCyte’s unaudited condensed results of operations for the periods presented are summarized below (in thousands): Three Months Ended March 31, 2019 2018 Condensed Statement of Operations (1): Research and development expense $ 1,343 $ 1,461 General and administrative expense 2,449 1,787 Sales and marketing expense 205 658 Loss from operations (3,997) (3,906) Net loss (3,864) (3,778)

Sale of Significant Ownership I

Sale of Significant Ownership Interest in AgeX to Juvenescence Limited	3 Months Ended
	Mar. 31, 2019
Sale Of Significant Ownership Interest In Agex To Juvenescence Limited
Sale of Significant Ownership Interest in AgeX to Juvenescence Limited	5. Sale of Significant Ownership Interest in AgeX to Juvenescence Limited On August 30, 2018, BioTime entered into a Stock Purchase Agreement with Juvenescence Limited and AgeX, pursuant to which BioTime sold 14.4 million shares of common stock of AgeX to Juvenescence for $3.00 per share, or an aggregate purchase price of $43.2 million (the “Purchase Price”). Juvenescence paid $10.8 million of the Purchase Price at closing, issued an unsecured convertible promissory note dated August 30, 2018 in favor of BioTime for $21.6 million (the “Promissory Note”), and paid $10.8 million on November 2, 2018. The Stock Purchase Agreement contains customary representations, warranties and indemnities from BioTime relating to the business of AgeX, including an indemnity cap of $4.3 million, which is subject to certain exceptions. The transactions contemplated by the Stock Purchase Agreement are referred to as the Juvenescence Transaction in this Report. The Promissory Note bears interest at 7% per annum, with principal and accrued interest payable at maturity on August 30, 2020. The Promissory Note cannot be prepaid prior to maturity or conversion. On the maturity date, if a “Qualified Financing” (as defined below) has not occurred, BioTime will have the right, but not the obligation, to convert the principal balance of the Promissory Note and accrued interest then due into shares of Series A preferred stock of Juvenescence at a conversion price of $15.60. Upon the occurrence of a Qualified Financing on or before the maturity date, the principal balance of the Promissory Note and accrued interest will automatically convert into a number of shares of the class of equity securities of Juvenescence sold in the Qualified Financing, at the price per share at which the Juvenescence securities are sold in the Qualified Financing; and, if AgeX common stock is listed on a national securities exchange in the U.S., the number of shares of the class of equity securities issuable upon conversion may be increased depending on the market price of AgeX common stock. A Qualified Financing is generally defined as an underwritten initial public offering of Juvenescence equity securities in which gross proceeds are not less than $50.0 million. The Promissory Note is not transferable, except in connection with a change of control of BioTime. For the three months ended March 31, 2019, BioTime recognized $378,000 in interest income on the Promissory Note. As of March 31, 2019, the principal and accrued interest balance of the Promissory Note was $22.5 million. Shareholder Agreement BioTime and Juvenescence entered into a Shareholder Agreement, dated August 30, 2018, setting forth the governance, approval and voting rights of the parties with respect to their holdings of AgeX common stock, including rights of representation on the AgeX Board of Directors, approval rights, preemptive rights, rights of first refusal and co-sale and drag-along and tag-along rights for so long as either BioTime or Juvenescence continue to own at least 15% of the outstanding shares of AgeX common stock. Under the Shareholder Agreement, Juvenescence and BioTime each had the right to designate two persons to a six-member AgeX Board of Directors, with the remaining two individuals to be independent of Juvenescence and BioTime. Following Juvenescence’s payment of $10.8 million on November 2, 2018 under the Stock Purchase Agreement, Juvenescence had the right to designate an additional member of the AgeX Board of Directors. As of April 30, 2019, Juvenescence has not exercised such right. Immediately following the AgeX Distribution on November 28, 2018 (see Note 6), BioTime owned In connection with the Juvenescence Transaction, the termination provision of the Shared Facilities Agreement (see Note 10) entitling AgeX or BioTime to terminate the agreement upon six months advance written notice was amended. Pursuant to the amendment, following the deconsolidation of AgeX from BioTime’s consolidated financial statements on August 30, 2018 (see Notes 6 and 10), each party retains the right to terminate the Shared Facilities Agreement at any time by giving the other party six months advance written notice, but BioTime may not do so prior to September 1, 2020. On May 7, 2019, AgeX provided written notice that it will terminate its use of BioTime’s office and laboratory facilities as of July 31, 2019. The other provisions of the Shared Facilities Agreement remain in place at this time.

Deconsolidation and Distributio

Deconsolidation and Distribution of AgeX	3 Months Ended
	Mar. 31, 2019
Deconsolidation And Distribution Of Agex
Deconsolidation and Distribution of AgeX	6. Deconsolidation and Distribution of AgeX Deconsolidation of AgeX On August 30, 2018, BioTime sold 14.4 million shares of the common stock of AgeX to Juvenescence (see Note 5). Immediately before that sale, BioTime and Juvenescence owned 80.4% and 5.6%, respectively, of AgeX’s outstanding common stock. Immediately following that sale, BioTime and Juvenescence owned 40.2% and 45.8%, respectively, of AgeX’s outstanding common stock. As a result, on August 30, 2018, AgeX was no longer a subsidiary of BioTime and, as of that date, BioTime experienced a “loss of control” of AgeX, as defined by GAAP. Loss of control is deemed to have occurred when, among other things, a parent company owns less than a majority of the outstanding common stock of a subsidiary, lacks a controlling financial interest in the subsidiary, and is unable to unilaterally control the subsidiary through other means such as having, or being able to obtain, the power to elect a majority of the subsidiary’s Board of Directors based solely on contractual rights or ownership of shares representing a majority of the voting power of the subsidiary’s voting securities. All of these loss-of-control factors were present with respect to BioTime’s ownership interest in AgeX as of August 30, 2018. In connection with the Juvenescence Transaction discussed in Note 5 and the AgeX Deconsolidation on August 30, 2018, in accordance with ASC 810-10-40-5, BioTime recorded a gain on deconsolidation of $78.5 million, which includes a financial reporting gain on the sale of the AgeX shares of $39.2 million, during the year ended December 31, 2018, included in other income and expenses, net, in the consolidated statements of operations. Distribution of AgeX Shares On November 28, 2018, BioTime distributed 12.7 million shares of AgeX common stock owned by BioTime to holders of BioTime common stock, on a pro rata basis, in the ratio of one share of AgeX common stock for every 10 shares of BioTime common stock owned. The AgeX Distribution was accounted for at fair value as a dividend-in-kind in the aggregate amount of $34.4 million, which was Because BioTime has an accumulated deficit in its consolidated shareholders’ equity, the entire fair value of the AgeX Distribution was charged against common stock equity included in the consolidated statements of changes in shareholders’ equity for the year ended December 31, 2018. Immediately following the AgeX Distribution, BioTime owned 1.7 million shares of AgeX common stock, all of which it still owns, and which represents approximately 4.6% of AgeX’s outstanding common stock as of March 31, 2019 and which shares BioTime holds as marketable equity securities

Property and Equipment, Net

Property and Equipment, Net	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Property and Equipment, Net	7. Property and Equipment, Net At March 31 March 31, 2019 December 31, 2018 (unaudited) Equipment, furniture and fixtures $ 4,424 $ 3,842 Leasehold improvements 2,746 3,910 Right-of-use assets (1) 4,946 - Accumulated depreciation and amortization (3,198) (3,185) Property and equipment, net 8,918 4,567 Construction in progress - 1,268 Property and equipment, net, and construction in progress $ 8,918 $ 5,835 (1) BioTime adopted ASC 842 on January 1, 2019. For additional information on this standard and right-of-use assets and liabilities see Notes 2 and 15. Property and equipment at both March 31, 2019 and December 31, 2018 includes $146,000 in financing leases. Depreciation and amortization expense amounted to $269,000 and $281,000 for the three months ended March 31, 2019 and 2018, respectively. Construction in progress Construction in progress of $1.3 million as of December 31, 2018 entirely relates to the leasehold improvements made at Cell Cure’s lease facilities in Jerusalem, Israel, primarily financed by the landlord. The leasehold improvements were substantially completed in December 2018 and the assets placed in service in January 2019 (see adoption of ASC 842 impact discussed in Notes 2 and 15).

Goodwill and Intangible Assets,

Goodwill and Intangible Assets, Net	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets, Net	8. Goodwill and Intangible Assets, Net At March 31 net consisted of the following (in thousands): March 31, 2019 December 31, 2018 (unaudited) Goodwill (1) $ 12,977 $ - Intangible assets: Acquired IPR&D – OPC1 (from the Asterias Merger) (2) $ 31,700 $ - Acquired IPR&D – VAC2 (from the Asterias Merger) (2) 14,840 - Intangible assets subject to amortization: Acquired patents 19,010 19,010 Acquired royalty contracts (2) 650 Other 10 10 Total intangible assets 66,210 19,020 Accumulated amortization (16,381 ) (15,895 ) Intangible assets, net $ 49,829 $ 3,125 (1) Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger (see Note 3). (2) See Note 3 for information on the Asterias Merger which was consummated on March 8, 2019. BioTime recognized in research and development expenses $485,000 and $582,000 of amortization expense in each of the three months ended March 31

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	3 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
Accounts Payable and Accrued Liabilities	9. Accounts Payable and Accrued Liabilities At March 31 March 31, 2019 December 31, 2018 (unaudited) Accounts payable (1) $ 1,379 $ 2,359 Accrued compensation (2) 3,457 2,456 Accrued liabilities (3) 2,476 1,639 Other current liabilities 24 9 Total $ 7,336 $ 6,463 (1) Includes $0.1 million of transaction costs related to the Asterias Merger (see Note 3) recorded outside of the business combination. (2) Includes $2.0 million of change of control and related transaction costs related to the Asterias Merger (see Note 3) recorded outside of the business combination. (3) Includes $0.6 million of transaction costs related to the Asterias Merger (see Note 3) recorded outside of the business combination. In connection with the Asterias Merger, several Asterias employees were terminated as of the Asterias Merger date. Three of these employees had employment agreements with Asterias which entitled them to change in control and separation payments in the aggregate of $2.0 million, which such conditions were met on the Asterias Merger date. Accordingly, $2.0 million was accrued and recorded in general and administrative expenses on the merger date and paid in April 2019. Additionally, BioTime entered into a plan of termination with substantially all other previous employees of Asterias with potential separation payments in the aggregate of $0.5 million. Termination dates for these individuals range from May 31, 2019 to June 28, 2019. These employees must provide services related to the transition and be an employee of the combined company as of their date of termination in order to receive separation benefits. Since the employees are required to render future services after the merger date, BioTime will record the aggregate liability ratably over their respective service periods from the Asterias Merger date through the above termination dates, in accordance with ASC 420, Exit or Disposal Cost Obligations

Related Party Transactions

Related Party Transactions	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Related Party Transactions	10. Related Party Transactions Shared Facilities and Service Agreements with Affiliates The receivables from affiliates shown on the condensed consolidated balance sheet as of December 31, 2018, primarily represent amounts owed to BioTime by OncoCyte and AgeX under separate Shared Facilities and Service Agreements (each a “Shared Facilities Agreement”), with amounts owed by OncoCyte comprising most of that amount. These outstanding amounts were paid in full in the first quarter of 2019. Under the terms of the Shared Facilities Agreements, BioTime allows OncoCyte and AgeX to use BioTime’s premises and equipment located at BioTime’s headquarters in Alameda, California for the purpose of conducting business. BioTime also provides accounting, billing, bookkeeping, payroll, treasury, payment of accounts payable, and other similar administrative services to OncoCyte and AgeX. BioTime may also provide the services of attorneys, accountants, and other professionals who may provide professional services to BioTime and its other subsidiaries. BioTime also has provided OncoCyte and AgeX with the services of laboratory and research personnel, including BioTime employees and contractors, for the performance of research and development work for OncoCyte and AgeX at the premises. BioTime charges OncoCyte and AgeX a “Use Fee” for services provided and for use of BioTime facilities, equipment, and supplies. For each billing period, BioTime prorates and allocates to OncoCyte and AgeX costs incurred, including costs for services of BioTime employees and use of equipment, insurance, leased space, professional services, software licenses, supplies and utilities. The allocation of costs depends on key cost drivers, including actual documented use, square footage of facilities used, time spent, costs incurred by BioTime for OncoCyte and AgeX, or upon proportionate usage by BioTime, OncoCyte and AgeX, as reasonably estimated by BioTime. BioTime, at its discretion, has the right to charge OncoCyte and AgeX a 5% markup on such allocated costs. The allocated cost of BioTime employees and contractors who provide services is based upon the number of hours or estimated percentage of efforts of such personnel devoted to the performance of services. The Use Fee is determined and invoiced to OncoCyte and AgeX on a regular basis, generally monthly or quarterly. Each invoice is payable in full within 30 days after receipt. Any invoice, or portion thereof, not paid in full when due will bear interest at the rate of 15% per annum until paid, unless the failure to make a payment is due to any inaction or delay in making a payment by BioTime. March 31 In addition to the Use Fee, OncoCyte and AgeX reimburse BioTime for any out of pocket costs incurred by BioTime for the purchase of office supplies, laboratory supplies, and other goods and materials and services for the account or use of OncoCyte or AgeX. BioTime is not obligated to purchase or acquire any office supplies or other goods and materials or any services for OncoCyte or AgeX, and if any such supplies, goods, materials or services are obtained, BioTime may arrange for the suppliers to invoice OncoCyte or AgeX directly The Shared Facilities Agreements remain in effect until a party gives the other party written notice that the Shared Facilities Agreement will terminate on December 31 of that year, or unless it is otherwise terminated under another provision of the agreement. In addition, BioTime and AgeX may each terminate their Shared Facilities Agreement prior to December 31 of the year by giving the other party written six months’ notice to terminate, but BioTime may not do so prior to September 1, 2020 In the aggregate, BioTime charged Use Fees to OncoCyte and AgeX as follows (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Research and development $ 232 $ 220 General and administrative 493 171 Total use fees $ 725 391 The Use Fees charged to OncoCyte and AgeX shown above are not reflected in revenues, but instead BioTime’s general and administrative expenses and research and development expenses are shown net of those charges in the condensed consolidated statements of operations. BioTime accounts for receivables from affiliates, net of payables to affiliates, if any, for similar shared services and other transactions BioTime’s consolidated subsidiaries may enter into with nonconsolidated affiliates. BioTime and the affiliates record those receivables and payables on a net basis since BioTime and the affiliates intend to exercise a right of offset of the receivable and the payable and to settle the balances net by having the party that owes the other party pay the net balance owed Transactions with Ascendance Biotechnology, Inc. On March 21, 2018, AgeX and Ascendance Biotechnology, Inc. (“Ascendance”), an equity method investee of AgeX and former equity method investee of BioTime, entered into an Asset Purchase Agreement (the “Asset Agreement”) in which AgeX purchased for $800,000 in cash certain assets consisting primarily of in-process research and development assets related to stem cell derived cardiomyocytes (heart muscle cells) to be developed by AgeX. The transaction was considered an asset acquisition rather than a business combination in accordance with ASC 805-50, Business Combinations Disposition of ownership interest in Ascendance On March 23, 2018, Ascendance was acquired by a third party in a merger through which AgeX received approximately $3.2 million in cash for its shares of Ascendance common stock. AgeX recognized a $3.2 million gain on the sale of its equity method investment in Ascendance, which is included in other income and expenses, net, for the three months ended March 31, 2018. Other related party transactions In February 2018, Alfred D. Kingsley, the Chairman of BioTime’s Board of Directors and a former officer and director of AgeX, BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime on a month-by-month basis by one of its directors at an amount that approximates his cost (see Note 15). In April 2019, BioTime issued 251,835 shares of BioTime common stock to Broadwood Partners, L.P., an Asterias and BioTime shareholder, in exchange for the settlement of Asterias Warrants in connection with the Asterias Merger (see Note 3).

Shareholders' Equity

Shareholders' Equity	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Shareholders' Equity	11. Shareholders’ Equity Preferred Shares BioTime is authorized to issue 2,000,000 preferred shares. The preferred shares may be issued in one or more series as the board of directors may determine by resolution. The board of directors is authorized to fix the number of shares of any series of preferred shares and to determine or alter the rights, preferences, privileges, and restrictions granted to or imposed on the preferred shares as a class, or upon any wholly unissued series of any preferred shares. The board of directors may, by resolution, increase or decrease (but not below the number of shares of such series then outstanding) the number of shares of any series of preferred shares subsequent to the issue of shares of that series. There are no preferred shares issued and outstanding. Common Shares At March 31 March 31 In April 2017, BioTime entered into a Controlled Equity Offering SM March 31 BioTime agreed to pay Cantor Fitzgerald a commission of 3.0% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cantor Fitzgerald with customary indemnification and contribution rights. The Sales Agreement may be terminated by Cantor Fitzgerald or BioTime at any time upon notice to the other party, or by Cantor Fitzgerald at any time in certain circumstances, including the occurrence of a material and adverse change in BioTime’s business or financial condition that makes it impractical or inadvisable to market the shares or to enforce contracts for the sale of the shares. Reconciliation of Changes in Shareholder's Equity The following tables document the changes in shareholder's equity for the periods from December 31, 2017 to March 31, 2018 and December 31, 2018 to March 31, 2019 (unaudited and in thousands). Preferred Shares Common Shares Noncontrolling Accumulated Other Total Number of Shares Amount Number of Shares Amount Accumulated Deficit Interest/ (Deficit) Comprehensive Income/(Loss) Shareholders’ Equity BALANCE AT DECEMBER 31, 2017 - $ - 126,866 $ 378,487 $ (216,297 ) $ 1,622 $ 451 $ 164,263 Cumulative-effect adjustment for adoption of ASU 2016-01 on January 1, 2018 - - - - 328 - (328 ) - Cumulative-effect adjustment for adoption of Accounting Standard Codification, Topic 606, on January 1, 2018 - - - - 101 - - 101 Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes - - 3 (7 ) - - - (7 ) Stock-based compensation - - - 809 - - - 809 Stock-based compensation in subsidiaries - - - - - 175 - 175 Sale of subsidiary warrants in AgeX - - - - - 737 - 737 Subsidiary financing transactions with noncontrolling interests – AgeX - - - (103 ) - 103 - - Foreign currency translation adjustments - - - - - - 75 75 NET LOSS - - - - (63,548 ) (150 ) - (63,698 ) BALANCE AT MARCH 31, 2018 - $ - 126,869 $ 379,186 $ (279,416 ) $ 2,487 $ 198 $ 102,455 Preferred Shares Common Shares Noncontrolling Accumulated Other Total Number of Shares Amount Number of Shares Amount Accumulated Deficit Interest/ (Deficit) Comprehensive Income/(Loss) Shareholders’ Equity BALANCE AT DECEMBER 31, 2018 - $ - 127,136 $ 354,270 $ (261,856 ) $ (1,594 ) $ 1,426 $ 92,246 Shares issued in connection with the Asterias Merger - - 24,696 32,353 - - - 32,353 Shares retired in connection with the Asterias Merger - - (2,622 ) (3,435 ) - - - (3,435 ) Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes - - 118 (75 ) - - - (75 ) Stock-based compensation - - - 1,361 - - - 1,361 Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services - - 60 79 - - - 79 Adjustment upon adoption of ASC 842 - - - - 143 - - 143 Tax effect of accumulated other comprehensive income - - - - - - (732 ) (732 ) NET INCOME/(LOSS) - - - - 39,310 (14 ) - 39,296 BALANCE AT MARCH 31, 2019 - $ - 149,388 $ 384,553 $ (222,403 ) $ (1,608 ) $ 694 $ 161,236 Warrants BioTime (previously Asterias) Warrants – Liability Classified In March 2019, in connection with the closing of the Asterias Merger, BioTime assumed outstanding Asterias Warrants. Cell Cure Warrants – Liability Classified Cell Cure has two sets of issued warrants. Warrants to purchase 24,566 Cell Cure ordinary shares at an exercise price of $40.5359 were issued to Hadasit Bio-Holdings, Ltd. in July 2017. These warrants expire in July 2022. Warrants to purchase 13,738 Cell Cure ordinary shares at exercise prices ranging from $32.02 to $40.00 per share have been issued to consultants. These warrants expire in October 2020 and January 2024. ASC 815 requires freestanding financial instruments, such as warrants, with exercise prices denominated in currencies other than the functional currency of the issuer to be accounted for as liabilities at fair value, with all subsequent changes in fair value after the issuance date to be recorded as gains or losses in the consolidated statements of operations. As of March 31

Stock-Based Awards

Stock-Based Awards	3 Months Ended
	Mar. 31, 2019
Share-based Payment Arrangement [Abstract]
Stock-Based Awards	12. Stock-Based Awards Equity Incentive Plan Awards BioTime adopted a 2012 Equity Incentive Plan (the “2012 Plan”), under which a maximum of 16,000,000 common shares are available for the grant of stock options, restricted stock, restricted stock units and stock appreciation rights. In January and February 2019, BioTime granted stock options to purchase 1.7 million common shares with exercise prices ranging from $1.08 to $1.14 per share to its employees, including to its new Chief Financial Officer hired in January 2019, under the 2012 Plan. These grants are subject to the customary vesting terms and conditions in accordance with the 2012 Plan. A summary of BioTime’s 2012 Plan activity and other stock option awards granted outside of the 2012 Plan related information is as follows (in thousands, except per share amounts): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price December 31, 2018 1,885 13,867 402 $ 2.44 AgeX distribution adjustment 117 (2) 3 - Restricted stock units vested - - (129) - Options granted (1,788) 1,788 - 1.14 Options exercised - - - - Options forfeited/cancelled 769 (769) - 1.92 March 31, 2019 983 14,884 276 2.81 Options exercisable at March 31, 2019 8,927 $ 3.21 At the effective time of the Asterias Merger, BioTime assumed sponsorship of the Asterias 2013 Equity Incentive Plan (the “Asterias Equity Plan”), with references to Asterias and Asterias common stock therein to be deemed references to BioTime and BioTime common stock. There were 7,309,184 shares available under Asterias Equity Plan immediately before the closing of the Asterias Merger, which became 5,189,520 shares immediately following the Asterias Merger. The shares available under the Asterias Equity Plan will be for awards granted to those former Asterias employees who continued as BioTime employees upon consummation of the Asterias Merger. A summary of activity under the Asterias Equity Plan from the closing date of the Asterias Merger through March 31, 2019 is as follows (in thousands, except per share amounts): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price March 8, 2019 5,190 - - $ - Options granted (490) 490 - 1.59 Options exercised - - - - Options forfeited/cancelled - - - - March 31, 2019 4,700 490 - 1.59 Options exercisable at March 31, 2019 - $ - Stock-based compensation expense The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions noted in the following table Three Months Ended March 31, (unaudited) 2019 2018 Expected life (in years) 6.04 5.87 Risk-free interest rates 2.5 % 2.6 % Volatility 64.0 % 56.1 % Dividend yield - % - % Operating expenses include stock-based compensation expense as follows (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Research and development $ 122 $ 193 General and administrative 1,318 791 Total stock-based compensation expense $ 1,440 $ 984 The expense related to 84,940 shares of Asterias restricted stock unit awards that immediately vested on the closing of the Asterias Merger and converted into the right to receive shares of BioTime common stock based on the Merger Exchange Ratio, resulting in 60,304 shares of BioTime common stock issued on March 8, 2019, which were included in stock-based compensation expense for the three months ended March 31, 2019. The expense was not included as part of the purchase price of the Asterias Merger because these awards were principally attributable to post-combination services.

Income Taxes

Income Taxes	3 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	13. Income Taxes The provision for income taxes for interim periods is generally determined using an estimated annual effective tax rate as prescribed by ASC 740-270, Income Taxes, Interim Reporting For items that BioTime cannot reliably estimate on an annual basis (principally unrealized gains or losses generated by changes in the market prices of the OncoCyte, and AgeX shares of common stock BioTime holds, and prior to March 8, 2019, Asterias shares BioTime held), BioTime uses the actual year to date effective tax rate rather than an estimated annual effective tax rate to determine the tax effect of each item, including the use of all available net operating losses and other credits or deferred tax assets. Although the deconsolidation of OncoCyte was not a taxable transaction to BioTime and did not create a current income tax payment obligation to BioTime, the market value of the shares of OncoCyte common stock BioTime holds creates a deferred tax liability to BioTime based on the closing prices of the shares, less BioTime’s tax basis in the shares. The deferred tax liability generated by the OncoCyte shares that BioTime holds as of March 31 source of future taxable income to BioTime, as prescribed by ASC 740-10-30-17, that will more likely than not result in the realization of its deferred tax assets to the extent of the deferred tax liability. March 31 Prior to the Asterias Merger discussed in Note 3, the Asterias shares of common stock BioTime held generated similar deferred tax liabilities to BioTime as the OncoCyte shares discussed above. As of the Asterias Merger date and due to Asterias becoming a wholly-owned subsidiary of BioTime, the Asterias deferred tax liabilities were eliminated with a corresponding adjustment to BioTime’s valuation allowance, resulting in no tax provision or benefit from this adjustment. On March 23, 2018, Ascendance was acquired by a third party in a merger through which AgeX received approximately $3.2 million in cash for its shares of Ascendance common stock. For financial reporting purposes, AgeX recognized a $3.2 million gain as a sale of its equity method investment in Ascendance. The income tax consequences of the AgeX Deconsolidation are discussed below. The Juvenescence Transaction discussed in was a taxable event for BioTime that resulted in a gross taxable gain of approximately $29.4 million, which BioTime fully offset with available net operating losses (“NOL”) and NOL carryforwards, resulting in no net income taxes due. accordance with ASC 740, primarily representing BioTime’s difference between book and tax basis of AgeX common stock on the AgeX Deconsolidation date. This deferred tax liability was fully offset by a corresponding release of BioTime’s valuation allowance on deferred tax assets, resulting in no income tax provision or benefit from the AgeX Deconsolidation. The deferred tax liabilities on BioTime’s investments in OncoCyte, Asterias and AgeX are considered to be sources of taxable income as prescribed by ASC 740-10-30-17 that will more likely than not result in the realization of its deferred tax assets to the extent of those deferred tax liabilities, thereby reducing the need for a valuation allowance. The distribution of AgeX shares of common stock to BioTime shareholders (see Note 6) on November 28, 2018 was a taxable event for BioTime that resulted in a gross taxable gain of approximately $26.4 million, which was fully offset by NOL carryforwards, resulting in no income taxes due. In connection with the Asterias Merger, a deferred tax liability of $13.0 million was recorded as part of the acquisition accounting (see Note 3). The deferred tax liability (“DTL”) is related to fair value adjustments for the assets and liabilities acquired in the Asterias Merger, principally consisting of IPR&D. This estimate of deferred taxes was determined based on the excess of the estimated fair values of the acquired assets and liabilities over the tax basis of the assets and liabilities acquired. The statutory tax rate was applied, as appropriate, to the adjustment based on the jurisdiction in which the adjustment is expected to occur. This estimate of deferred income tax liabilities is preliminary and is subject to change based upon BioTime’s final determination of the fair value of assets acquired and liabilities assumed. Because the IPR&D (prior to completion or abandonment of the R&D) is considered an indefinite-lived asset for accounting purposes, the fair value of the IPR&D on the acquisition date creates a deferred income tax liability in accordance with ASC 740. This DTL is computed using the fair value of the IPR&D assets on the acquisition date multiplied by BioTime’s respective federal and state income tax rates. While this DTL would reverse on impairment or sale or commencement of amortization of the related intangible assets, those events are not anticipated under ASC 740 for purposes of predicting reversal of a temporary difference to support the realization of deferred tax assets, except for certain deferred tax assets and credit carryforwards that are also indefinite in nature as of the Asterias Merger date, which may be considered for reversal under ASC 740 as further discussed below. A valuation allowance is provided when it is more likely than not that some portion of the deferred tax assets will not be realized. For federal and state income tax purposes, as a result of the deconsolidation of AgeX, Asterias and OncoCyte and the deferred tax liabilities generated from the market values of AgeX, Asterias and OncoCyte shares from the respective deconsolidation dates, including the changes to those deferred tax liabilities due to changes in the AgeX, Asterias and OncoCyte stock prices, BioTime’s deferred tax assets exceeded its deferred tax liabilities as of December 31, 2018. As a result, BioTime established a full valuation allowance as of December 31, 2018 due to the uncertainty of realizing future tax benefits from its net operating loss carryforwards and other deferred tax assets. For the three months ended March 31, 2019, BioTime reversed a portion of its valuation allowance. The partial reversal of the historical valuation allowance is related to BioTime’s deferred tax assets and credit carryforwards and is due to the acquired taxable temporary differences, primarily consisting of the acquired IPR&D discussed above and in Notes 3 and 8. ASC 740 allows for deferred tax assets and credit carryforwards, that are both available and indefinite in nature, to be used against similar deferred tax liabilities as a source of income to support the realization of those deferred tax assets and credit carryforwards. Any benefit recognized from such a reversal of the valuation allowance is recorded outside of the acquisition accounting. Accordingly, the $4.4 million valuation allowance release and the corresponding tax benefit was primarily related to state research and development credits, including current year federal net operating losses generated for the three months ended March 31, 2019, both of which are available and indefinite in nature. BioTime did not record any provision or benefit for income taxes for the three months ended March 31

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	3 Months Ended
	Mar. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Supplemental Cash Flow Information	14. Supplemental Cash Flow Information Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the three months ended March 31, 2019 and 2018 are as follows (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Supplemental disclosures of non-cash investing and financing activities: Issuance of common stock for the Asterias Merger (Note 3) $ 32,353 $ - Assumption of liabilities in the Asterias Merger (Note 3) 1,136 - Assumptions of warrants in the Asterias Merger (Note 3) 867 -

Commitments and Contingencies

Commitments and Contingencies	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	15. Commitments and Contingencies Alameda Lease In December 2015, BioTime entered into a lease for approximately 30,795 square feet of rentable space in two buildings located in an office park in Alameda, California (the “Alameda Lease”). The term of the Alameda Lease commenced effective February 1, 2016 and expires on January 31, 2023, unless BioTime exercises its option to renew the lease for an additional five years. Base rent under the Alameda Lease beginning on February 1, 2019 is $70,521 per month and will increase by approximately 3% annually on every February 1 thereafter during the lease term. Prior to the adoption of ASC 842 on January 1, 2019 (see Note 2), the lease payments allocated to the lease liability for leasehold improvements reimbursed by the landlord were amortized as debt service on that liability using the effective interest method over the lease term. See Note 2 discussion of the impact of adoption of ASC 842 on January 1, 2019, and below for the ROU assets and liabilities recorded in connection with the adoption of ASC 842 as of, and during the three months ended March 31, 2019 for the Alameda Lease. In addition to base rent, BioTime will pay a pro rata portion of increases in certain expenses, including real property taxes, utilities (to the extent not separately metered to the leased space) and the landlord’s operating expenses, over the amounts of those expenses incurred by the landlord. As security for the performance of its obligations under the Alameda Lease, BioTime provided the landlord with a security deposit of approximately $424,000, which was reduced to $78,000 on January 24, 2019 in accordance with the terms of the lease. The security deposit amount is considered restricted cash and $78,000 is included in deposits and other long-term assets as of March 31, 2019 (see Note 2). New York Leased Office Space BioTime currently pays $5,050 per month for the use of approximately 900 square feet of office space in New York City, which is made available to BioTime for use in conducting meetings and other business affairs, on a month-by-month basis, by one of its directors at an amount that approximates his cost. This lease was not in the scope of ASC 842 because it is a month to month lease (see Note 2). Cell Cure Lease Cell Cure leases 728.5 square meters (approximately 7,842 square feet) of office and laboratory space in Jerusalem, Israel under a lease that expires December 31, 2020, with two options to extend the lease for 5 years each. Base monthly rent is NIS 37,882 (approximately US $11,000 per month using the December 31, 2018 exchange rate). In addition to base rent, Cell Cure pays a pro rata share of real property taxes and certain costs related to the operation and maintenance of the building in which the leased premises are located. On January 28, 2018, Cell Cure entered into another lease agreement for an additional 934 square meters (approximately 10,054 square feet) of office space in the same facility in Jerusalem, Israel under a lease that expires on December 31, 2025, with two options to extend the lease for 5 years each (the “January 2018 Lease”). The January 2018 Lease commenced on April 1, 2018 and included a leasehold improvement construction allowance of up to NIS 4,000,000 (approximately up to $1.1 million using the December 31, 2018 exchange rate) from the landlord. The leasehold improvements were completed in December 2018 and the entire allowance was used. Beginning on January 1, 2019, combined base rent and construction allowance payments for the January 2018 Lease are NIS 93,827 per month (approximately $26,000 per month). Prior to the adoption of ASC 842 on January 1, 2019, Cell Cure was considered the owner of the tenant improvements under construction under ASC 840-40-55 as Cell Cure, among other things, had the primary obligation to pay for construction costs and Cell Cure retains exclusive use of the leased facilities for its office, research and cGMP manufacturing facility requirements after construction was completed (“build to suit” lease). In accordance with the ASC 840 guidance, amounts expended by Cell Cure for construction was reported as construction in progress, and the proceeds received from the landlord, if any, are reported as a lease liability. As As of March 31, 2019, the landlord has paid the complete leasehold improvement construction allowance and the property has been placed in service. See Note 2 discussion of the impact of adoption of ASC 842 on January 1, 2019, and below for the ROU assets and liabilities recorded in connection with the adoption of ASC 842 as of, and during the three months ended March 31, 2019 for the Cell Cure and January 2018 Leases above (the “Cell Cure Leases”). In December 2018, Cell Cure made a $388,000 deposit required under the January 2018 Lease, which amount is included in deposits and other long-term assets on the consolidated balance sheet as of December 31, 2018, to be held as restricted cash during the term of the January 2018 Lease. Adoption of ASC 842 The below tables provide the amounts recorded in connection with the adoption of ASC 842 as of, and during the three months ended March 31, 2019, for BioTime’s operating and financing leases, as applicable. Supplemental cash flow information related to leases was as follows (in thousands): Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 331 Operating cash flows from financing leases 7 Financing cash flows from financing leases 6 Supplemental balance sheet information related to leases was as follows (in thousands, except lease term and discount rate): March 31, 2019 Operating leases Right-of-use assets, net $ 4,678 Right-of-use lease liabilities, current 923 Right-of-use lease liabilities, noncurrent 4,016 Total operating lease liabilities $ 4,939 Financing leases Property and equipment, gross $ 146 Accumulated depreciation (28) Property and equipment, net $ 118 Current liabilities 32 Long-term liabilities 102 Total finance lease liabilities $ 134 Weighted average remaining lease term Operating leases 4.9 years Finance leases 4.2 years Weighted average discount rate Operating leases 9.1% Finance leases 10.0% Future minimum lease commitments are as follows (in thousands): Operating Leases Finance Leases Year Ending December 31, 2019 $ 994 $ 33 2020 1,339 43 2021 1,245 36 2022 1,251 36 2023 393 15 Thereafter 1,015 - Total lease payments $ 6,237 $ 163 Less imputed interest (1,298 ) (29 ) Total $ 4,939 $ 134 Research and Option Agreement On January 5, 2019, BioTime and Orbit Biomedical Limited (“Orbit”) entered into a Research and Option Agreement (the “Orbit Agreement”) for an exclusive partnership to assess Orbit’s vitrectomy-free subretinal injection device as a means of delivering OpRegen in BioTime’s ongoing Phase I/IIa clinical trial. The term of the Orbit Agreement is for one year unless certain research activities and related data specified in the Orbit Agreement is obtained sooner. The access fees payable by BioTime to Orbit for its technology and the injection device are $2.5 million in the aggregate, of which $1.25 million was paid in January 2019 upon execution of the Orbit Agreement and the remaining $1.25 million payment is due on the earlier of (i) six months from the Orbit Agreement date or, (ii) upon completion of certain collaborative research activities using the Orbit technology for the OpRegen Phase I/IIa clinical trial, as specified in the Orbit Agreement. In addition to the access fees, BioTime will pay Orbit for costs of consumables, training services, travel costs and other out of pocket expenses incurred by Orbit for performing services under the Orbit Agreement. BioTime has exclusive rights to the Orbit technology and its injection device for the treatment of dry-AMD during the term of the Orbit Agreement and may extend the term for an additional three months by paying Orbit a cash fee of $500,000. For the three months ended March 31, 2019, BioTime amortized $0.6 million of the upfront payment fee included in research and development expenses. As of March 31, 2019, BioTime had not incurred the remaining $1.25 million access fee. Litigation BioTime will be subject to various claims and contingencies in the ordinary course of its business, including those related to litigation, business transactions, employee-related matters, and others. When BioTime is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, BioTime will record a liability for the loss. If the loss is not probable or the amount of the loss cannot be reasonably estimated, BioTime will disclose the claim if the likelihood of a potential loss is reasonably possible and the amount involved could be material. BioTime is not aware of any claims likely to have a material adverse effect on its financial condition or results of operations. On February 19, 2019, a putative shareholder class action lawsuit was filed (captioned Lampe v. Asterias Biotherapeutics, Inc. et al BioTime believes that the allegations lack merit and intends to vigorously defend all claims asserted. in accordance with ASC 450, Contingencies Employment contracts BioTime has entered into employment agreements with certain executive officers. Under the provisions of the agreements, BioTime may be required to incur severance obligations for matters relating to changes in control, as defined in the agreements, and involuntary terminations. Indemnification In the normal course of business, BioTime may provide indemnifications of varying scope under BioTime’s agreements with other companies or consultants, typically BioTime’s clinical research organizations, investigators, clinical sites, suppliers and others. Pursuant to these agreements, BioTime will generally agree to indemnify, hold harmless, and reimburse the indemnified parties for losses and expenses suffered or incurred by the indemnified parties arising from claims of third parties in connection with the use or testing of BioTime’s products and services. Indemnification provisions could also cover third party infringement claims with respect to patent rights, copyrights, or other intellectual property pertaining to BioTime products and services. The term of these indemnification agreements will generally continue in effect after the termination or expiration of the particular research, development, services, or license agreement to which they relate. The potential future payments BioTime could be required to make under these indemnification agreements will generally not be subject to any specified maximum amount. Historically, BioTime has not been subject to any claims or demands for indemnification. BioTime also maintains various liability insurance policies that provide BioTime with insurance against claims or demands for indemnification in specified circumstances. As a result, BioTime believes the fair value of these indemnification agreements is minimal. Accordingly, BioTime has not recorded any liabilities for these agreements as of March 31 Royalty obligations and license fees BioTime and its subsidiaries or affiliates are parties to certain licensing agreements with research institutions, universities and other parties for the rights to use those licenses and other intellectual property in conducting research and development activities. These licensing agreements provide for the payment of royalties by BioTime or the applicable party to the agreement on future product sales, if any. In addition, in order to maintain these licenses and other rights during the product development, BioTime or the applicable party to the contract must comply with various conditions including the payment of patent related costs and annual minimum maintenance fees. Annual minimum maintenance fees are approximately $135,000 to $150,000 per year. The research and development risk for these products is significant. License fees and related expenses under these agreements were immaterial for the periods presented in the condensed consolidated interim financial statements provided herein. Grants Under the terms of the grant agreement between Cell Cure and Israel Innovation Authority (“IIA”) (formerly the Office of the Chief Scientist of Israel) of the Ministry of Economy and Industry, for the development of OpRegen ® OpRegen ® Accordingly, pursuant to ASC 730-20, the grant is considered a contract to perform research and development services for others and grant revenue is recognized as the related research and development expenses are incurred (see Note 2). Israeli law pertaining to such government grants contain various conditions, including substantial penalties and restrictions on the transfer of intellectual property, or the manufacture, or both, of products developed under the grant outside of Israel, as defined by the IIA.

Basis of Presentation, Liquid_2

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Policies)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Principles of Consolidation	Principles of consolidation BioTime’s condensed consolidated interim financial statements include the accounts of its subsidiaries. The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of March 31, 2019. Subsidiary Field of Business BioTime Ownership Country Asterias BioTherapeutics, Inc. Cell therapy clinical development programs in spinal cord injury and oncology 100% USA Cell Cure Neurosciences Ltd. (“Cell Cure”) Products to treat age-related macular degeneration 99% (1) Israel ES Cell International Pte. Ltd. (“ESI”) Stem cell products for research, including clinical grade cell lines produced under cGMP 100% Singapore OrthoCyte Corporation (“OrthoCyte”) Developing bone grafting products for orthopedic diseases and injuries 99.8% USA (1) Includes shares owned by BioTime and ESI. For the three months ended March 31, 2018, BioTime’s unaudited consolidated results include AgeX’s consolidated results for the full period presented. As a result of the AgeX Deconsolidation, beginning on August 30, 2018 (a) AgeX’s consolidated financial statements and consolidated results are no longer a part of BioTime’s condensed consolidated interim financial statements and results, and (b) the fair value of AgeX common stock held by BioTime is now reflected on BioTime’s condensed consolidated balance sheet and the changes in the fair value of those shares during the applicable reporting period are reflected as gains or losses in BioTime’s condensed consolidated statements of operations included in other income and expenses, net. All material intercompany accounts and transactions have been eliminated in consolidation. As of March 31, 2019, BioTime consolidated its direct and indirect wholly-owned or majority-owned subsidiaries because BioTime has the ability to control their operating and financial decisions and policies through its ownership, and the noncontrolling interest is reflected as a separate element of shareholders’ equity on BioTime’s consolidated balance sheets.
Liquidity	Liquidity Since inception, BioTime has incurred significant operating losses and has funded its operations primarily through the issuance of equity securities, sale of common stock of AgeX, a former subsidiary, receipt of research grants, royalties from product sales, license revenues and sales of research products. At March 31, 2019, BioTime had an accumulated deficit of approximately $222.4 million, working capital of $21.9 million and shareholders’ equity of $161.2 million. BioTime has evaluated its projected cash flows and believes that its $27.1 million of cash, cash equivalents and marketable equity securities at March 31, 2019, plus the value of its equity investment in OncoCyte ($58.0 million based on the closing price of OncoCyte common stock on March 31, 2019), provide sufficient cash, cash equivalents, and liquidity to carry out BioTime’s current planned operations through at least twelve months from the issuance date of the consolidated financial statements included herein. Although BioTime has no plans to liquidate its investment in OncoCyte, if BioTime needs near term working capital or liquidity to supplement its cash and cash equivalents for its operations, BioTime may sell some, or all, of its OncoCyte shares, as necessary. The AgeX Distribution was completed on November 28, 2018 when AgeX became a publicly traded company (see Note 6). BioTime continues to hold a minority interest in AgeX that may be a source of additional liquidity to BioTime as a marketable equity security. If the promissory note issued by Juvenescence in favor of BioTime discussed in Note 5 is converted into shares of Juvenescence common stock prior to its maturity date, the Juvenescence common stock may be a marketable security that BioTime may use to supplement its liquidity, as needed. If such promissory note is not converted, it is payable in cash, plus accrued interest, at maturity on August 30, 2020. On March 8, 2019, with the consummation of the Asterias Merger, Asterias became BioTime’s wholly-owned subsidiary. BioTime began consolidating Asterias’ operations and results with its operations and results beginning on March 8, 2019 (see Note 3). As BioTime integrates Asterias’ operations into its own, BioTime expects to make extensive reductions in headcount and to reduce non-clinical related spend, in each case, as compared to Asterias’ operations before the Asterias Merger. BioTime’s projected cash flows are subject to various risks and uncertainties, and the unavailability or inadequacy of financing to meet future capital needs could force BioTime to modify, curtail, delay, or suspend some or all aspects of its planned operations. BioTime’s determination as to when it will seek new financing and the amount of financing that it will need will be based on BioTime’s evaluation of the progress it makes in its research and development programs, any changes to the scope and focus of those programs, any changes in grant funding for certain of those programs, and projection of future costs, revenues, and rates of expenditure. BioTime may be required to delay, postpone, or cancel clinical trials or limit the number of clinical trial sites, unless it is able to obtain adequate financing. In addition, BioTime BioTime cannot assure that adequate financing will be available on favorable terms, if at all. Sales of additional equity securities by BioTime or its subsidiaries and affiliates could result in the dilution of the interests of current shareholders.
Business Combinations	Business Combinations BioTime accounts for business combinations, such as the Asterias Merger completed in March 2019, in accordance with ASC Topic 805, which requires the purchase price to be measured at fair value. When the purchase consideration consists entirely of shares of BioTime’s common stock, BioTime calculates the purchase price by determining the fair value, as of the acquisition date, of shares issued in connection with the closing of the acquisition. BioTime recognizes estimated fair values of the tangible assets and intangible assets acquired, including in-process research and development (“IPR&D”), and liabilities assumed as of the acquisition date, and records as goodwill any amount of the fair value of the tangible and intangible assets acquired and liabilities assumed in excess of the purchase price.
Equity Method Investments at Fair Value	Equity method investments at fair value BioTime uses the equity method of accounting when it has the ability to exercise significant influence, but not control, as determined in accordance with GAAP, over the operating and financial policies of a company. For equity method investments which BioTime has elected to measure at fair value, unrealized gains and losses are reported in the consolidated statements of operations in other income and expenses, net. As further discussed in Note 4, BioTime has elected to account for its OncoCyte shares at fair value using the equity method of accounting because beginning on February 17, 2017, the respective date on which BioTime deconsolidated OncoCyte, BioTime has not had control of OncoCyte, as defined by GAAP, but continues to exercise significant influence over this company. Under the fair value method, BioTime’s value in shares of common stock it holds in OncoCyte is marked to market at each balance sheet date using the closing price of OncoCyte common stock on the NYSE American multiplied by the number of shares of OncoCyte held by BioTime, with changes in the fair value of the OncoCyte shares included in other income and expenses, net, in the consolidated statements of operations. The OncoCyte shares are considered level 1 assets as defined by ASC 820, Fair Value Measurements and Disclosures Prior to the Asterias Merger completed on March 8, 2019 discussed in Note 3, BioTime accounted for its Asterias shares held at fair value, using the equity method of accounting.
Revenue Recognition	Revenue Recognition During the first quarter of 2018, BioTime adopted Financial Accounting Standards Board (“FASB”) Accounting Standards Update (“ASU”) ASU 2014-09, Revenues from Contracts with Customers (Topic 606) BioTime recognizes revenue in a manner that depicts the transfer of control of a product or a service to a customer and reflects the amount of the consideration it is entitled to receive in exchange for such product or service. In doing so, BioTime follows a five-step approach: (i) identify the contract with a customer, (ii) identify the performance obligations in the contract, (iii) determine the transaction price, (iv) allocate the transaction price to the performance obligations, and (v) recognize revenue when (or as) the customer obtains control of the product or service. BioTime considers the terms of a contract and all relevant facts and circumstances when applying the revenue recognition standard. BioTime applies the revenue recognition standard, including the use of any practical expedients, consistently to contracts with similar characteristics and in similar circumstances. BioTime’s largest source of revenue is currently related to government grants. In applying the provisions of ASU 2014-09, BioTime has determined that government grants are out of the scope of ASU 2014-09 because the government entities do not meet the definition of a “customer”, as defined by ASU 2014-09, as there is not considered to be a transfer of control of good or services to the government entities funding the grant. BioTime has, and will continue to, account for grants received to perform research and development services in accordance with ASC 730-20, Research and Development Arrangements Deferred grant revenues represent grant funds received from the governmental funding agencies for which the allowable expenses have not yet been incurred as of the balance sheet date reported. As of March 31, 2019, deferred grant revenue was immaterial.
Basic And Diluted Net Income (Loss) Per Share Attributable to Common Shareholders	Basic and diluted net income (loss) per share attributable to common shareholders Basic earnings per share is calculated by dividing net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, net of unvested restricted stock or restricted stock units, subject to repurchase by BioTime, if any, during the period. Diluted earnings per share is calculated by dividing the net income or loss attributable to BioTime common shareholders by the weighted average number of common shares outstanding, adjusted for the effects of potentially dilutive common shares issuable under outstanding stock options and warrants, using the treasury-stock method, convertible preferred stock, if any, using the if-converted method, and treasury stock held by subsidiaries, if any. For the three months ended March 31, 2019, BioTime reported net income attributable to common shareholders, and therefore, did an analysis of common share equivalents to determine their impact on diluted net income, if any. For the three months ended March 31, 2018, The following weighted average common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Stock options 14,628 9,243 Warrants (1) - 9,395 BioTime Warrants (2) 533 - Restricted stock units 278 56 (1) The warrants expired on October 1, 2018. (2) Although the BioTime warrants are classified as liabilities, these warrants are considered for dilutive earnings per share calculations in accordance with ASC 260, Earnings Per Share
Lease Accounting and Impact of Adoption of the New Lease Standard	Lease accounting and impact of adoption of the new lease standard On January 1, 2019, BioTime adopted ASU 2016-02, Leases Codification Improvements to Topic 842, Leases, Leases (Topic 842): Targeted improvements, BioTime management determines if an arrangement is a lease at inception. Leases are classified as either financing or operating, with classification affecting the pattern of expense recognition in the consolidated statements of operations. When determining whether a lease is a finance lease or an operating lease, ASC 842 does not specifically define criteria to determine “major part of remaining economic life of the underlying asset” and “substantially all of the fair value of the underlying asset.” For lease classification determination, BioTime continues to use (i) greater to or equal to 75% to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) greater to or equal to 90% to determine whether the present value of the sum of lease payments is substantially the fair value of the underlying asset. Under the available practical expedients, BioTime accounts for the lease and non-lease components as a single lease component. BioTime recognizes right-of-use (“ROU”) assets and lease liabilities for leases with terms greater than twelve months in the condensed consolidated balance sheet. ROU assets represent BioTime’s right to use an underlying asset during the lease term and lease liabilities represent BioTime’s obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of BioTime’s leases do not provide an implicit rate, BioTime uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. BioTime uses the implicit rate when readily determinable. The operating lease ROU asset also includes any lease payments made and excludes lease incentives. BioTime’s lease terms may include options to extend or terminate the lease when it is reasonably certain that BioTime will exercise that option. Lease expense for lease payments is recognized on a straight-line basis over the lease term. Operating leases are included as right-of-use assets in property and equipment (see Note 15), and ROU lease liabilities, current and long-term, in the condensed consolidated balance sheets. Financing leases are included in property and equipment, and in financing lease liabilities, current and long-term, in BioTime’s condensed consolidated balance sheets. In connection with the adoption on ASC 842 on January 1, 2019, BioTime derecognized net book value of leasehold improvements and corresponding lease liabilities of $1.9 million and $2.0 million, respectively, which was the carrying value of certain operating leases as of December 31, 2018, included in property and equipment and lease liabilities, respectively, recorded pursuant to build to suit lease accounting under the previous ASC 840 lease standard. The derecognition of these amounts from the superseded ASC 840 lease standard was offset by a cumulative effect adjustment of $0.1 million as a reduction of BioTime’s accumulated deficit on January 1, 2019. These build to suit leases were primarily related to the Alameda and the Cell Cure Leases described in Note 15. ASC 842 requires build to suit leases recognized on BioTime’s consolidated balance sheets as of December 31, 2018 to be derecognized upon the adoption of the new lease standard and be recognized in accordance with the new standard on January 1, 2019. The adoption of ASC 842 had a material impact in BioTime’s consolidated balance sheets, with the most significant impact resulting from the recognition of ROU assets and lease liabilities for operating leases with remaining terms greater than twelve months on the adoption date (see Note 15). BioTime’s accounting for financing leases (previously referred to as “capital leases”) remained substantially unchanged.
Other Recently Adopted Accounting Pronouncements	Other recently adopted accounting pronouncements Adoption of ASU 2016-18 , Statement of Cash Flows (Topic 230) Statement of Cash Flows (Topic 230): Restricted Cash The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheet dates that comprise the total of the same such amounts shown in the condensed consolidated statements of cash flows for all periods presented herein and effected by the adoption of ASU 2016-18 (in thousands): March 31, 2019 December 31, 2018 March 31, 2018 December 31, 2017 (unaudited) (unaudited) Cash and cash equivalents $ 18,011 $ 23,587 $ 29,827 $ 36,838 Restricted cash included in prepaid expenses and other current assets (see Note 15) - 346 346 - Restricted cash included in deposits and other long-term assets (see Note 15) 679 466 78 847 Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows $ 18,690 $ 24,399 $ 30,251 $ 37,685 Adoption of ASU 2016-01, Financial Instruments–Overall: Recognition and Measurement of Financial Assets and Financial Liabilities Changes to the current GAAP model under ASU 2016-01 primarily affects the accounting for equity investments, financial liabilities under the fair value option, and the presentation and disclosure requirements for financial instruments. In addition, ASU 2016-01 clarified guidance related to the valuation allowance assessment when recognizing deferred tax assets resulting from unrealized losses on available-for-sale debt securities. The accounting for other financial instruments, such as loans, investments in debt securities, and financial liabilities is largely unchanged. The more significant amendments are to equity investments in unconsolidated entities. In accordance with ASU No. 2016-01, all equity investments in unconsolidated entities (other than those accounted for using the equity method of accounting) will generally be measured at fair value through earnings. There will no longer be an available-for-sale classification (changes in fair value reported in other comprehensive income) for equity securities with readily determinable fair values. marketable equity securities policy, BioTime adopted ASU 2016-01 on January 1, 2018. Adoption of ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting - Compensation - Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting Recently Issued Accounting Pronouncements Not Yet Adopted In August 2018, the FASB issued ASU 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement

Basis of Presentation, Liquid_3

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Tables)	3 Months Ended
	Mar. 31, 2019
Accounting Policies [Abstract]
Schedule of Biotime's Ownership of Outstanding Shares of Its Subsidiaries	The following table reflects BioTime’s ownership, directly or through one or more subsidiaries, of the outstanding shares of its operating subsidiaries as of March 31, 2019. Subsidiary Field of Business BioTime Ownership Country Asterias BioTherapeutics, Inc. Cell therapy clinical development programs in spinal cord injury and oncology 100% USA Cell Cure Neurosciences Ltd. (“Cell Cure”) Products to treat age-related macular degeneration 99% (1) Israel ES Cell International Pte. Ltd. (“ESI”) Stem cell products for research, including clinical grade cell lines produced under cGMP 100% Singapore OrthoCyte Corporation (“OrthoCyte”) Developing bone grafting products for orthopedic diseases and injuries 99.8% USA (1) Includes shares owned by BioTime and ESI.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following weighted average common share equivalents were excluded from the computation of diluted net income (loss) per common share for the periods presented because including them would have been antidilutive (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Stock options 14,628 9,243 Warrants (1) - 9,395 BioTime Warrants (2) 533 - Restricted stock units 278 56 (1) The warrants expired on October 1, 2018. (2) Although the BioTime warrants are classified as liabilities, these warrants are considered for dilutive earnings per share calculations in accordance with ASC 260, Earnings Per Share
Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash	The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the condensed consolidated balance sheet dates that comprise the total of the same such amounts shown in the condensed consolidated statements of cash flows for all periods presented herein and effected by the adoption of ASU 2016-18 (in thousands): March 31, 2019 December 31, 2018 March 31, 2018 December 31, 2017 (unaudited) (unaudited) Cash and cash equivalents $ 18,011 $ 23,587 $ 29,827 $ 36,838 Restricted cash included in prepaid expenses and other current assets (see Note 15) - 346 346 - Restricted cash included in deposits and other long-term assets (see Note 15) 679 466 78 847 Total cash, cash equivalents, and restricted cash as shown in the condensed consolidated statements of cash flows $ 18,690 $ 24,399 $ 30,251 $ 37,685

Asterias Merger (Tables)

Asterias Merger (Tables)	3 Months Ended
	Mar. 31, 2019
Business Combinations [Abstract]
Schedule of Merger Consideration Transferred	The calculation of the purchase price for the Asterias Merger and the Merger Consideration transferred on March 8, 2019 was as follows (in thousands, except for share and per share amounts): BioTime (38% ownership interest) Shareholders other than BioTime (approximate 62% ownership interest) Total Outstanding Asterias common stock as of March 8, 2019 21,747,569 34,783,333 (1) 56,530,902 (1) Exchange ratio 0.710 0.710 0.710 BioTime common stock issuable 15,440,774 (2) 24,695,898 (3) 40,136,672 Per share price of BioTime common stock as of March 8, 2019 $ 1.31 $ 1.31 $ 1.31 Purchase price (in $000s) $ 20,227 (2) $ 32,353 $ 52,580 (1) Includes 81,810 shares of Asterias restricted stock unit awards that immediately vested on March 8, 2019 and converted into the right to receive shares of BioTime common stock based on the Merger Exchange Ratio, resulting in 58,085 shares of BioTime common stock issued on March 8, 2019 as part of the Merger Consideration. These restricted stock units were principally attributable to pre-combination services and included as part of the purchase price in accordance with ASC 805 . See Note 12 for Asterias restricted stock units that vested on the closing of the Asterias Merger attributable to post-combination services that were recorded outside of the purchase price as an immediate charge to stock-based compensation expense. (2) Estimated fair value for BioTime’s previously held 38% ownership interest in Asterias common stock is part of the total purchase price of Asterias for purposes of the purchase price allocation under ASC 805 and for BioTime’s adjustment of its 38% interest to fair value at the effective date of the Asterias Merger and immediately preceding the consolidation of Asterias’ results with BioTime. No actual shares of BioTime common stock were issued to BioTime in connection with the Asterias Merger. (3) Net of a de minimis number of fractional shares which were paid in cash.
Schedule of Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed	The following table sets forth a preliminary allocation of the purchase price to Asterias’ tangible and identifiable intangible assets acquired and liabilities assumed on the closing of the Asterias Merger, with the excess recorded as goodwill (in thousands): Assets acquired: Cash and cash equivalents $ 3,117 Prepaid expenses and other assets, current and noncurrent 660 Machinery and equipment 369 Long-lived intangible assets - royalty contracts 650 Acquired in-process research and development (“IPR&D”) 46,540 Total assets acquired 51,336 Liabilities assumed: Accrued liabilities and accounts payable 1,136 Liability classified warrants 867 Deferred license revenue 200 Long-term deferred income tax liability 12,965 Total liabilities assumed 15,168 Net assets acquired, excluding goodwill (a) 36,168 Fair value of BioTime common stock held by Asterias (b) 3,435 Total purchase price (c) 52,580 Estimated goodwill (c-a-b) $ 12,977
Schedule of Valuation of Identifiable Intangible Assets and Their Estimated Useful Lives	The valuation of identifiable intangible assets and their estimated useful lives are as follows (in thousands, except for useful life): ​ Preliminary Estimated Asset Fair Value Useful Life (Years) In process research and development (“IPR&D”) $ 46,540 n/a Royalty contracts 650 5 $ 47,190
Schedule of Supplemental Pro Forma Financial Information	The unaudited supplemental pro forma financial information for the periods presented is as follows (in thousands, except per share data): Three months ended March 31 ​ 2019 2018 Pro forma net revenue $ 877 $ 974 Pro forma operating expenses (15,368) (17,430) Pro forma loss from operations (14,491) (16,456) Pro forma other income (loss), net 40,537 (33,137) Pro forma net income (loss) attributable to BioTime shareholders 26,039 (45,038) Pro forma net income/(loss) per share, basic and diluted $ 0.20 $ (0.30)

Equity Method of Accounting f_2

Equity Method of Accounting for Common Stock of Oncocyte, at Fair Value (Tables)	3 Months Ended
	Mar. 31, 2019
OncoCyte Corporation [Member]
Schedule of Equity Method Investments [Line Items]
Schedule of Condensed Results of Operations and Balance sheet Information	OncoCyte’s unaudited condensed results of operations for the periods presented are summarized below (in thousands): Three Months Ended March 31, 2019 2018 Condensed Statement of Operations (1): Research and development expense $ 1,343 $ 1,461 General and administrative expense 2,449 1,787 Sales and marketing expense 205 658 Loss from operations (3,997) (3,906) Net loss (3,864) (3,778)

Property and Equipment, Net (Ta

Property and Equipment, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment, Net	At March 31 March 31, 2019 December 31, 2018 (unaudited) Equipment, furniture and fixtures $ 4,424 $ 3,842 Leasehold improvements 2,746 3,910 Right-of-use assets (1) 4,946 - Accumulated depreciation and amortization (3,198) (3,185) Property and equipment, net 8,918 4,567 Construction in progress - 1,268 Property and equipment, net, and construction in progress $ 8,918 $ 5,835 (1) BioTime adopted ASC 842 on January 1, 2019. For additional information on this standard and right-of-use assets and liabilities see Notes 2 and 15.

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets, Net (Tables)	3 Months Ended
	Mar. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill and Intangible Assets, Net	At March 31 net consisted of the following (in thousands): March 31, 2019 December 31, 2018 (unaudited) Goodwill (1) $ 12,977 $ - Intangible assets: Acquired IPR&D – OPC1 (from the Asterias Merger) (2) $ 31,700 $ - Acquired IPR&D – VAC2 (from the Asterias Merger) (2) 14,840 - Intangible assets subject to amortization: Acquired patents 19,010 19,010 Acquired royalty contracts (2) 650 Other 10 10 Total intangible assets 66,210 19,020 Accumulated amortization (16,381 ) (15,895 ) Intangible assets, net $ 49,829 $ 3,125 (1) Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger (see Note 3). (2) See Note 3 for information on the Asterias Merger which was consummated on March 8, 2019.

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	3 Months Ended
	Mar. 31, 2019
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	At March 31 March 31, 2019 December 31, 2018 (unaudited) Accounts payable (1) $ 1,379 $ 2,359 Accrued compensation (2) 3,457 2,456 Accrued liabilities (3) 2,476 1,639 Other current liabilities 24 9 Total $ 7,336 $ 6,463 (1) Includes $0.1 million of transaction costs related to the Asterias Merger (see Note 3) recorded outside of the business combination. (2) Includes $2.0 million of change of control and related transaction costs related to the Asterias Merger (see Note 3) recorded outside of the business combination. (3) Includes $0.6 million of transaction costs related to the Asterias Merger (see Note 3) recorded outside of the business combination.

Related Party Transactions (Tab

Related Party Transactions (Tables)	3 Months Ended
	Mar. 31, 2019
Related Party Transactions [Abstract]
Schedule of Related Party Transactions	In the aggregate, BioTime charged Use Fees to OncoCyte and AgeX as follows (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Research and development $ 232 $ 220 General and administrative 493 171 Total use fees $ 725 391

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	3 Months Ended
	Mar. 31, 2019
Equity [Abstract]
Schedule of Reconciliation of Changes in Shareholders' Equity	The following tables document the changes in shareholder's equity for the periods from December 31, 2017 to March 31, 2018 and December 31, 2018 to March 31, 2019 (unaudited and in thousands). Preferred Shares Common Shares Noncontrolling Accumulated Other Total Number of Shares Amount Number of Shares Amount Accumulated Deficit Interest/ (Deficit) Comprehensive Income/(Loss) Shareholders’ Equity BALANCE AT DECEMBER 31, 2017 - $ - 126,866 $ 378,487 $ (216,297 ) $ 1,622 $ 451 $ 164,263 Cumulative-effect adjustment for adoption of ASU 2016-01 on January 1, 2018 - - - - 328 - (328 ) - Cumulative-effect adjustment for adoption of Accounting Standard Codification, Topic 606, on January 1, 2018 - - - - 101 - - 101 Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes - - 3 (7 ) - - - (7 ) Stock-based compensation - - - 809 - - - 809 Stock-based compensation in subsidiaries - - - - - 175 - 175 Sale of subsidiary warrants in AgeX - - - - - 737 - 737 Subsidiary financing transactions with noncontrolling interests – AgeX - - - (103 ) - 103 - - Foreign currency translation adjustments - - - - - - 75 75 NET LOSS - - - - (63,548 ) (150 ) - (63,698 ) BALANCE AT MARCH 31, 2018 - $ - 126,869 $ 379,186 $ (279,416 ) $ 2,487 $ 198 $ 102,455 Preferred Shares Common Shares Noncontrolling Accumulated Other Total Number of Shares Amount Number of Shares Amount Accumulated Deficit Interest/ (Deficit) Comprehensive Income/(Loss) Shareholders’ Equity BALANCE AT DECEMBER 31, 2018 - $ - 127,136 $ 354,270 $ (261,856 ) $ (1,594 ) $ 1,426 $ 92,246 Shares issued in connection with the Asterias Merger - - 24,696 32,353 - - - 32,353 Shares retired in connection with the Asterias Merger - - (2,622 ) (3,435 ) - - - (3,435 ) Shares issued upon vesting of restricted stock units, net of shares retired to pay employees’ taxes - - 118 (75 ) - - - (75 ) Stock-based compensation - - - 1,361 - - - 1,361 Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services - - 60 79 - - - 79 Adjustment upon adoption of ASC 842 - - - - 143 - - 143 Tax effect of accumulated other comprehensive income - - - - - - (732 ) (732 ) NET INCOME/(LOSS) - - - - 39,310 (14 ) - 39,296 BALANCE AT MARCH 31, 2019 - $ - 149,388 $ 384,553 $ (222,403 ) $ (1,608 ) $ 694 $ 161,236

Stock-Based Awards (Tables)

Stock-Based Awards (Tables)	3 Months Ended
	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options	The fair value of each option award is estimated on the date of grant using a Black-Scholes option pricing model applying the weighted-average assumptions noted in the following table Three Months Ended March 31, (unaudited) 2019 2018 Expected life (in years) 6.04 5.87 Risk-free interest rates 2.5 % 2.6 % Volatility 64.0 % 56.1 % Dividend yield - % - %
Schedule of Stock Based Compensation Expense	Operating expenses include stock-based compensation expense as follows (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Research and development $ 122 $ 193 General and administrative 1,318 791 Total stock-based compensation expense $ 1,440 $ 984
2012 Equity Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity	A summary of BioTime’s 2012 Plan activity and other stock option awards granted outside of the 2012 Plan related information is as follows (in thousands, except per share amounts): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price December 31, 2018 1,885 13,867 402 $ 2.44 AgeX distribution adjustment 117 (2) 3 - Restricted stock units vested - - (129) - Options granted (1,788) 1,788 - 1.14 Options exercised - - - - Options forfeited/cancelled 769 (769) - 1.92 March 31, 2019 983 14,884 276 2.81 Options exercisable at March 31, 2019 8,927 $ 3.21
Asterias 2013 Equity Incentive Plan [Member] | Asterias Biotherapeutics, Inc. [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity	A summary of activity under the Asterias Equity Plan from the closing date of the Asterias Merger through March 31, 2019 is as follows (in thousands, except per share amounts): Shares Available for Grant Number of Options Outstanding Number of RSUs Outstanding Weighted Average Exercise Price March 8, 2019 5,190 - - $ - Options granted (490) 490 - 1.59 Options exercised - - - - Options forfeited/cancelled - - - - March 31, 2019 4,700 490 - 1.59 Options exercisable at March 31, 2019 - $ -

Supplemental Cash Flow Inform_2

Supplemental Cash Flow Information (Tables)	3 Months Ended
	Mar. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Schedule of Condensed Consolidated Statements of Cash Flows	Non-cash investing and financing transactions presented separately from the condensed consolidated statements of cash flows for the three months ended March 31, 2019 and 2018 are as follows (in thousands): Three Months Ended March 31, (unaudited) 2019 2018 Supplemental disclosures of non-cash investing and financing activities: Issuance of common stock for the Asterias Merger (Note 3) $ 32,353 $ - Assumption of liabilities in the Asterias Merger (Note 3) 1,136 - Assumptions of warrants in the Asterias Merger (Note 3) 867 -

Commitments and Contingencies (

Commitments and Contingencies (Tables)	3 Months Ended
	Mar. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Schedule of Supplemental Cash Flow Information Related to Leases	Supplemental cash flow information related to leases was as follows (in thousands): Three Months Ended March 31, 2019 Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 331 Operating cash flows from financing leases 7 Financing cash flows from financing leases 6
Schedule of Supplemental Balance Sheet Information Related to Leases	Supplemental balance sheet information related to leases was as follows (in thousands, except lease term and discount rate): March 31, 2019 Operating leases Right-of-use assets, net $ 4,678 Right-of-use lease liabilities, current 923 Right-of-use lease liabilities, noncurrent 4,016 Total operating lease liabilities $ 4,939 Financing leases Property and equipment, gross $ 146 Accumulated depreciation (28) Property and equipment, net $ 118 Current liabilities 32 Long-term liabilities 102 Total finance lease liabilities $ 134 Weighted average remaining lease term Operating leases 4.9 years Finance leases 4.2 years Weighted average discount rate Operating leases 9.1% Finance leases 10.0%
Schedule of Future Minimum Lease Commitments	Future minimum lease commitments are as follows (in thousands): Operating Leases Finance Leases Year Ending December 31, 2019 $ 994 $ 33 2020 1,339 43 2021 1,245 36 2022 1,251 36 2023 393 15 Thereafter 1,015 - Total lease payments $ 6,237 $ 163 Less imputed interest (1,298 ) (29 ) Total $ 4,939 $ 134

Organization and Business Ove_2

Organization and Business Overview (Details Narrative) $ in Thousands	Mar. 08, 2019USD ($)shares	Mar. 08, 2019USD ($)shares	Mar. 31, 2019Programshares	Mar. 07, 2019	Nov. 28, 2018shares
Number of cell therapy programs | Program			3
Parent Company [Member] | Common Stock [Member]
Ownership percentage			28.00%
Number of shares owned			14,700,000		1,700,000
Merger Consideration [Member] | Parent Company [Member]
Stock-for-stock transaction	24,695,898	24,695,898
Aggregate merger consideration amount | $	$ 32,400	$ 32,400
Merger Consideration [Member] | Asterias [Member]
Stock-for-stock transaction	0.71	0.71
Merger Consideration [Member] | Asterias [Member] | Restricted Stock [Member]
Stock-for-stock transaction	58,085	58,085
Merger Agreement [Member]
Ownership percentage				38.00%

Basis of Presentation, Liquid_4

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies (Details Narrative) - USD ($) $ in Thousands	Jan. 02, 2019	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Accumulated deficit		$ (222,403)	$ (261,856)
Working capital		21,900
Shareholders' equity		161,236	92,246	$ 102,455	$ 164,263
Cash and cash equivalents and marketable securities		27,100
Common stock, value		$ 384,553	$ 354,270
Debt instrument maturity date		Aug. 30, 2020
Lease payment rate, description		For lease classification determination, BioTime continues to use (i) greater to or equal to 75% to determine whether the lease term is a major part of the remaining economic life of the underlying asset and (ii) greater to or equal to 90% to determine whether the present value of the sum of lease payments is substantially of the fair value of the underlying asset.
Value of leasehold improvements	$ 1,900
Operating lease liabilities	2,000	$ 4,939
Cumulative effect adjustment	$ 100
OncoCyte Corporation [Member]
Common stock, value		$ 58,000

Basis of Presentation, Liquid_5

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Biotime's Ownership of Outstanding Shares of its Subsidiaries (Details)	Mar. 31, 2019
Asterias Biotherapeutics, Inc. [Member] | United States [Member]
Noncontrolling Interest [Line Items]
BioTime Ownership	100.00%
Cell Cure Neurosciences, Ltd. [Member] | Israel
Noncontrolling Interest [Line Items]
BioTime Ownership	99.00%	[1]
ES Cell International Pte, Ltd. [Member] | Singapore
Noncontrolling Interest [Line Items]
BioTime Ownership	100.00%
OrthoCyte Corporation [Member] | United States [Member]
Noncontrolling Interest [Line Items]
BioTime Ownership	99.80%
[1]	Includes shares owned by BioTime and ESI

Basis of Presentation, Liquid_6

Basis of Presentation, Liquidity and Summary of Significant Accounting Policies - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Details) - shares		3 Months Ended
		Mar. 31, 2019	Mar. 31, 2018
Stock Options [Member]
Antidilutive securities excluded from computation of earnings per share, amount		14,628	9,243
Warrants [Member]
Antidilutive securities excluded from computation of earnings per share, amount	[1]		9,395
BioTime Warrants [Member]
Antidilutive securities excluded from computation of earnings per share, amount	[2]	533
Restricted Stock Units [Member]
Antidilutive securities excluded from computation of earnings per share, amount		278	56
[1]	The warrants expired on October 1, 2018.
[2]	Although the BioTime warrants are classified as liabilities, these warrants are considered for dilutive earnings per share calculations in accordance with ASC 260, Earnings Per Share, and determined to be anti-dilutive for the period presented.

Summary of Significant Accounti

Summary of Significant Accounting Policies - Schedule of Reconciliation of Cash, Cash Equivalents, and Restricted Cash (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018	Mar. 31, 2018	Dec. 31, 2017
Accounting Policies [Abstract]
Cash and cash equivalents	$ 18,011	$ 23,587	$ 29,827	$ 36,838
Restricted cash included in prepaid expenses and other current assets		346	346
Restricted cash included in deposits and other long-term assets	679	466	78	847
Total cash, cash equivalents, and restricted cash as shown in the consolidated statements of cash flows	$ 18,690	$ 24,399	$ 30,251	$ 37,685

Asterias Merger (Details Narrat

Asterias Merger (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Mar. 08, 2019	Mar. 08, 2019	Sep. 30, 2018	Mar. 31, 2019	Mar. 31, 2018	May 08, 2019	Dec. 31, 2018	May 13, 2016
Closing price of common stock				$ 162,844			$ 93,840
Number of warrants issued to purchase of common stock								2,813,159
Fair value of warrants				$ (37)	$ 108
Common stock held in investment	2,621,811	2,621,811
Share price, per share	$ 1.31	$ 1.31					$ 0.62
Fair value of Equity method investment, shares				21,700
Fair value of Equity method investment, value	$ 20,200	$ 20,200					$ 13,500
General and Administrative [Member]
Acquisition related costs				$ 3,500
April, 2019 [Member]
Number of warrants issued to purchase of common stock				907,442
Fair value of warrants				$ 372
Common Stock [Member]
Number of warrants issued to purchase of common stock								2,959,559
Exercise price								$ 4.37
Warrant term								5 years
Warrant expiration date								May 13, 2021
BioTime Warrants [Member]
Exercise price				$ 6.15
Warrant expiration date				May 31, 2021
Fair value of warrants				$ 495
AST Clinical Program [Member]
Identifiable intangible asset acquired		46,500
Royalty Contracts [Member]
Useful life of asset				5 years
In Process Research and Development [Member]
Identifiable intangible asset acquired		31,700
Regenerative Medicine [Member]
Identifiable intangible asset acquired		$ 14,800
30 Days After the Closing of Asterian Merger [Member] | BioTime Warrants [Member]
Number of warrants issued to purchase of common stock				1,089,900
December 31, 2018 to March 8, 2019 [Member]
Unrealized loss				$ 6,700
December 31, 2017 to March 31, 2018 [Member]
Unrealized loss					$ 17,400
December 31, 2017 to March 31, 2018 [Member] | Maximum [Member]
Share price, per share					$ 2.25
December 31, 2017 to March 31, 2018 [Member] | Minimum [Member]
Share price, per share					$ 1.45
Parent Company [Member]
Number of warrants issued to purchase of common stock				1,997,340
Parent Company [Member] | April, 2019 [Member]
Fair value of warrants				$ 332
Exchange of shares				251,835
Exchange for cash				$ 40
Asterias [Member]
Upfront payment received			$ 1,000
Estimated purchase price			$ 200
Ownership interest				38.00%
Merger Consideration [Member] | Parent Company [Member]
Stock-for-stock transaction	24,695,898	24,695,898
Closing price of common stock						$ 32,400
Merger Consideration [Member] | Asterias [Member]
Stock-for-stock transaction	0.71	0.71
Merger Consideration [Member] | Asterias [Member] | Restricted Stock [Member]
Stock-for-stock transaction	58,085	58,085

Asterias Merger - Schedule of M

Asterias Merger - Schedule of Merger Consideration Transferred (Details) - Asterias Biotherapeutics, Inc. [Member] $ / shares in Units, $ in Thousands	Mar. 08, 2019USD ($)$ / sharesshares
Outstanding Asterias common stock	56,530,902	[1]
Exchange ratio	0.710
BioTime common stock issuable	40,136,672
Per share price of BioTime common stock | $ / shares	$ 1.31
Purchase price | $	$ 52,580
Shareholders Other than BioTime [Member]
Outstanding Asterias common stock	34,783,333	[1]
Exchange ratio	0.710
BioTime common stock issuable	24,695,898	[2]
Per share price of BioTime common stock | $ / shares	$ 1.31
Purchase price | $	$ 32,353
Parent Company [Member]
Outstanding Asterias common stock	21,747,569
Exchange ratio	0.710
BioTime common stock issuable	15,440,774	[3]
Per share price of BioTime common stock | $ / shares	$ 1.31
Purchase price | $	$ 20,227	[3]
[1]	Includes 81,810 shares of Asterias restricted stock unit awards that immediately vested on March 8, 2019 and converted into the right to receive shares of BioTime common stock based on the Merger Exchange Ratio, resulting in 58,085 shares of BioTime common stock issued on March 8, 2019 as part of the Merger Consideration. These restricted stock units were principally attributable to pre-combination services and included as part of the purchase price in accordance with ASC 805. See Note 12 for Asterias restricted stock units that vested on the closing of the Asterias Merger attributable to post-combination services that were recorded outside of the purchase price as an immediate charge to stock-based compensation expense.
[2]	Net of a de minimis number of fractional shares which were paid in cash.
[3]	Estimated fair value for BioTime's previously held 38% ownership interest in Asterias common stock is part of the total purchase price of Asterias for purposes of the purchase price allocation under ASC 805 and for BioTime's adjustment of its 38% interest to fair value at the effective date of the Asterias Merger and immediately preceding the consolidation of Asterias' results with BioTime. No actual shares of BioTime common stock were issued to BioTime in connection with the Asterias Merger.

Asterias Merger - Schedule of_2

Asterias Merger - Schedule of Merger Consideration Transferred (Details) (Parenthetical) - Asterias Biotherapeutics, Inc. [Member]	Mar. 08, 2019shares
Parent Company [Member]
Number of shares issued	58,085
Ownership interest	38.00%
Restricted Stock [Member]
Numbe rof restricted stock vested	81,810

Asterias Merger - Schedule of I

Asterias Merger - Schedule of Identifiable Tangible and Intangible Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2019	Dec. 31, 2018
Estimated goodwill (c-a-b)	[1]	$ 12,977
Asterias Biotherapeutics, Inc. [Member]
Cash and cash equivalents		3,117
Prepaid expenses and other assets, current and noncurrent		660
Machinery and equipment		369
Long-lived intangible assets - royalty contracts		650
Acquired in-process research and development ("IPR&D")		46,540
Total assets acquired		51,336
Accrued liabilities and accounts payable		1,136
Liability classified warrants		867
Deferred license revenue		200
Long-term deferred income tax liability		12,965
Total liabilities assumed		15,168
Net assets acquired, excluding goodwill (a)		36,168
Fair value of BioTime common stock held by Asterias (b)		3,435
Total purchase price (c)		52,580
Estimated goodwill (c-a-b)		$ 12,977
[1]	Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger (see Note 3).

Asterias Merger - Schedule of V

Asterias Merger - Schedule of Valuation of Identifiable Intangible Assets and Their Estimated Useful Lives (Details) - Asterias Biotherapeutics, Inc. [Member] $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Preliminary Estimated Asset Fair Value	$ 47,190
In Process Research and Development [Member]
Preliminary Estimated Asset Fair Value	$ 46,540
Useful Life (Years)	0 years
Royalty Contracts [Member]
Preliminary Estimated Asset Fair Value	$ 650
Useful Life (Years)	5 years

Asterias Merger - Schedule of S

Asterias Merger - Schedule of Supplemental Pro Forma Financial Information (Details) - Asterias Biotherapeutics, Inc. [Member] - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Pro forma net revenue	$ 877	$ 974
Pro forma operating expenses	(15,368)	(17,430)
Pro forma loss from operations	(14,491)	(16,456)
Pro forma other income (loss), net	40,537	(33,137)
Pro forma net income (loss) attributable to BioTime shareholders	$ 26,039	$ (45,038)
Pro forma net income/(loss) per share, basic and diluted	$ 0.20	$ (0.30)

Equity Method Accounting for Co

Equity Method Accounting for Common Stock of Oncocyte, at Fair Value (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 08, 2019	Dec. 31, 2018	Feb. 17, 2017
Closing Price per share			$ 1.31	$ 0.62
OncoCyte Corporation [Member]
Common stock at fair value					14,700,000
Fair value on investment	$ 58,000			$ 20,300
Closing Price per share	$ 3.95			$ 1.38
Unrealized (gain) loss on equity method investment in at fair value	$ 37,713	$ (37,419)

Equity Method Accounting for _2

Equity Method Accounting for Common Stock of Oncocyte, at Fair Value - Schedule of Condensed Results of Operations and Balance sheet Information (Details) - OncoCyte Corporation [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Research and development expense	$ 1,343	$ 1,461
General and administrative expense	2,449	1,787
Sales and marketing expense	205	658
Loss from operations	(3,997)	(3,906)
Net loss	$ (3,864)	$ (3,778)

Sale of Significant Ownership_2

Sale of Significant Ownership Interest in AgeX to Juvenescence Limited (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Nov. 02, 2018	Aug. 30, 2018	Mar. 31, 2019	Nov. 28, 2018
Debt instrument maturity date			Aug. 30, 2020
Parent Company [Member] | Common Stock [Member]
Number of shares owned			14,700,000	1,700,000
Common stock shares issued and outstanding percentage				4.80%
Juvenescence Limited [Member]
Number of share sold		14,400,000
Stock Purchase Agreement [Member] | Juvenescence Limited [Member]
Number of share sold		14,400,000
Sale of stock price per share		$ 3
Purchase price of shares		$ 43,200
Purchase price amount paid	$ 10,800
Indemnity cap		$ 4,300
Debt instrument interest rate		7.00%
Proceeds from public offering		$ 50,000
Stock Purchase Agreement [Member] | Juvenescence Limited [Member] | Series A Preferred Share [Member]
Debt conversion, price per share		$ 15.60
Stock Purchase Agreement [Member] | Juvenescence Limited [Member] | Promissory Note [Member]
Purchase price amount paid		$ 21,600
Debt instrument interest rate		7.00%
Debt instrument maturity date		Aug. 30, 2020
Interest income debt			$ 378
Promissory Note principal and accrued interest			$ 22,500
Stock Purchase Agreement [Member] | Juvenescence Limited [Member] | Closing of Transaction [Member]
Purchase price amount paid		$ 10,800
Shareholder Agreement [Member]
Shareholder agreement description		As provided in the Purchase Agreement, BioTime and Juvenescence entered into a Shareholder Agreement, dated August 30, 2018, setting forth the governance, approval and voting rights of the parties with respect to their holdings of AgeX common stock, including rights of representation on the AgeX Board of Directors, approval rights, preemptive rights, rights of first refusal and co-sale and drag-along and tag-along rights for so long as either BioTime or Juvenescence continue to own at least 15% of the outstanding shares of AgeX common stock.

Deconsolidation and Distribut_2

Deconsolidation and Distribution of AgeX (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Nov. 28, 2018	Aug. 30, 2018	Mar. 31, 2019	Dec. 31, 2018	Nov. 29, 2018
AgeX Therapeutics, Inc. [Member]
Gain on deconsolidation				$ 78,500
Gain on sale of shares				$ 39,200
Parent Company [Member]
Percentage of ownership before transaction		80.40%
Percentage of ownership after transaction		40.20%
Parent Company [Member] | Common Stock [Member]
Number of shares owned	1,700,000		14,700,000
Percentage of outstanding common stock			4.60%
Parent Company [Member] | Prorata Basis [Member]
Common stock, ratio description	one share of AgeX common stock for every 10 shares of BioTime common stock
Parent Company [Member] | Prorata Basis [Member] | Common Stock [Member]
Common shares issued	12,700,000
Dividend-in-kind	$ 34,400
Price per share					$ 2.71
Juvenescence Limited [Member]
Number of share sold		14,400,000
Percentage of ownership before transaction		5.60%
Percentage of ownership after transaction		45.80%

Property and Equipment, Net (De

Property and Equipment, Net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018
financing leases related to property and equipment	$ 146		$ 146
Depreciation and amortization expense	269	$ 281
Construction in progress			1,268
Cell Cure Neurosciences, Ltd. [Member]
Construction in progress			$ 1,300

Property and Equipment, Net - S

Property and Equipment, Net - Schedule of Property and Equipment, Net (Details) - USD ($) $ in Thousands		Mar. 31, 2019	Dec. 31, 2018
Property, Plant and Equipment [Line Items]
Accumulated depreciation and amortization		$ (3,198)	$ (3,185)
Property and equipment, net		8,918	5,835
Construction in progress			1,268
Property, plant and equipment, net, and construction in progress		8,918	5,835
Equipment, Furniture and Fixtures [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		4,424	3,842
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross		2,746	3,910
Right-of-Use Assets [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	[1]	$ 4,946
[1]	BioTime adopted ASC 842 on January 1, 2019. For additional information on this standard and right-of-use assets and liabilities see Notes 2 and 15.

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets, Net (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Research and Development Expenses [Member]
Amortization expense	$ 485	$ 582

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets, Net - Schedule of Goodwill and Intangible Assets, Net (Details) - USD ($) $ in Thousands		Mar. 31, 2019	Dec. 31, 2018
Goodwill	[1]	$ 12,977
Other		10	10
Total intangible assets		66,210	19,020
Accumulated amortization		(16,381)	(15,895)
Intangible assets, net		49,829	3,125
IPR&D - OPC1 [Member]
Total intangible assets	[2]	31,700
IPR&D - VAC2 [Member]
Total intangible assets	[2]	14,840
Patents [Member]
Total intangible assets		19,010	19,010
Royalty Contracts [Member]
Total intangible assets	[2]	$ 650
[1]	Goodwill represents the excess of the purchase price over the fair value of the net tangible and identifiable intangible assets acquired and liabilities assumed in the Asterias Merger (see Note 3).
[2]	See Note 3 for information on the Asterias Merger which was consummated on March 8, 2019.

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details Narrative) - USD ($) $ in Thousands		3 Months Ended
		Mar. 31, 2019	Dec. 31, 2018
Accrued compensation	[1]	$ 3,457	$ 2,456
Asterias Biotherapeutics, Inc. [Member]
Seperation payments		$ 500
Description of termination plan		Termination dates for these individuals range from May 31, 2019 to June 28, 2019.
Accrued Seperation payments		$ 100
Asterias Biotherapeutics, Inc. [Member] | General and Administrative [Member]
Accrued compensation		2,000
Asterias Biotherapeutics, Inc. [Member] | Three Employees Member [Member]
Seperation payments		$ 2,000
[1]	Includes $2.0 million of change of control and related transaction costs related to the Asterias Merger (see Note 3) recorded outside of the business combination.

Accounts Payable and Accrued _4

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) - USD ($) $ in Thousands		Mar. 31, 2019	Dec. 31, 2018
Payables and Accruals [Abstract]
Accounts payable	[1]	$ 1,379	$ 2,359
Accrued compensation	[2]	3,457	2,456
Accrued liabilities	[3]	2,476	1,639
Other current liabilities		24	9
Total		$ 7,336	$ 6,463
[1]	Includes $0.1 million of transaction costs related to the Asterias Merger (see Note 3) recorded outside of the business combination.
[2]	Includes $2.0 million of change of control and related transaction costs related to the Asterias Merger (see Note 3) recorded outside of the business combination.
[3]	Includes $0.6 million of transaction costs related to the Asterias Merger (see Note 3) recorded outside of the business combination.

Accounts Payable and Accrued _5

Accounts Payable and Accrued Liabilities - Schedule of Accounts Payable and Accrued Liabilities (Details) (Parenthetical) $ in Thousands	Mar. 31, 2019USD ($)
Accounts Payable [Member]
Transaction costs	$ 100
Accrued Compensation [Member]
Transaction costs	2,000
Accrued Liabilities [Member]
Transaction costs	$ 600

Related Party Transactions (Det

Related Party Transactions (Details Narrative)	Mar. 23, 2018USD ($)	Mar. 21, 2018USD ($)	Mar. 31, 2019USD ($)ft²shares	Mar. 31, 2018USD ($)	Feb. 28, 2018USD ($)$ / sharesshares	May 13, 2016shares
Purchase of In process research and development				$ 800,000
Warrants to purchase of shares | shares						2,813,159
April, 2019 [Member]
Warrants to purchase of shares | shares			907,442
Office Space in New York City [Member]
Rent per month			$ 5,050
Area of office space square feet | ft²			900
Ascendance Biotechnology, Inc [Member]
Purchase of In process research and development		$ 800,000
Accounts receivable		$ 200,000
AgeX Therapeutics, Inc. [Member]
Proceeds from issuance of common stock	$ 3,200,000
Gain on sale of equity method investment	$ 3,200,000			$ 3,200,000
Warrants to purchase of shares | shares					248,600
Warrant exercise price share | $ / shares					$ 2.50
AgeX Therapeutics, Inc. [Member] | Alfred D. Kingsley [Member]
Warrant exercise price share | $ / shares					$ 0.50
Warrants value					$ 124,300
Broadwood Partners, L.P [Member] | April, 2019 [Member]
Common shares issued | shares			251,835
OncoCyte Corporation and AgeX Therapeutics Inc [Member]
Markup rate on allocated costs			5.00%
Term of payment			30 days
Interest rate charged on unpaid and overdue invoices			15.00%

Related Party Transactions - Sc

Related Party Transactions - Schedule of Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2019	Dec. 31, 2018
Total use fees	$ 725	$ 391
Research and Development [Member]
Total use fees	232	220
General and Administrative [Member]
Total use fees	$ 493	$ 171

Shareholders' Equity (Details N

Shareholders' Equity (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	1 Months Ended	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018	Dec. 31, 2018	Jul. 31, 2017	Apr. 30, 2017	May 13, 2016
Preferred shares, shares authorized	2,000,000	2,000,000		2,000,000
Preferred shares, shares issued
Preferred shares, shares outstanding
Common stock, shares authorized	250,000,000	250,000,000		250,000,000
Common stock, no par value
Common stock, issued	149,388,000	149,388,000		127,136,000
Common stock, outstanding	149,388,000	149,388,000		127,136,000
Fair value of warrant		$ (37)	$ 108
Warrants issued to purchase ordinary shares							2,813,159
Cell Cure Warrants [Member] | Consultants [Member]
Warrants issued to purchase ordinary shares	13,738	13,738
Warrants expiring period, description		expiring in October 2020 and January 2024
Cell Cure [Member] | Long-term Liabilities [Member]
Warrants issued	$ 1,200	$ 1,200		$ 400
Hadasit Bio-Holdings, Ltd [Member]
Warrants issued to purchase ordinary shares					24,566
Warrants exercise price per share					$ 40.5359
Warrant expiration date					Jul. 31, 2022
April, 2019 [Member]
Fair value of warrant		$ 372
Warrants issued to purchase ordinary shares	907,442	907,442
Asterias Biotherapeutics, Inc. [Member]
Fair value of warrant		$ 495
Warrants issued to purchase ordinary shares	1,089,900	1,089,900
Warrants exercisable term	30 days
Warrants exercise price per share	$ 6.15	$ 6.15
Warrant expiration date	May 13, 2021	May 13, 2021
Asterias Biotherapeutics, Inc. [Member] | April, 2019 [Member]
Warrants outstanding	1,997,342	1,997,342
Warrants outstanding, settled	907,442	907,442
Fair value of warrant		$ 372
Maximum [Member] | Cell Cure Warrants [Member] | Consultants [Member]
Warrants exercise price per share	$ 40	$ 40
Minimum [Member] | Cell Cure Warrants [Member] | Consultants [Member]
Warrants exercise price per share	$ 32.02	$ 32.02
Cantor Fitzgerald & Co [Member]
Fair value available for grant		$ 24,200
Percentage of commission payable		3.00%
Cantor Fitzgerald & Co [Member] | Maximum [Member]
Aggregate offering price						$ 25,000

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Reconciliation of Changes in Shareholders' Equity (Details) - USD ($) $ in Thousands	Jan. 02, 2019	Mar. 31, 2019	Mar. 31, 2018
Beginning balance	$ 92,246	$ 92,246	$ 164,263
Cumulative-effect adjustment for adoption of Accounting Standard Codification	100
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes		(75)	(7)
Stock-based compensation		1,361	809
Stock-based compensation in subsidiaries			175
Sale of subsidiary warrants in AgeX			737
Subsidiary financing transactions with noncontrolling interests - AgeX
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services		79
Foreign currency translation adjustments		(732)	75
Shares issued in connection with the Asterias Merger		32,353
Shares retired in connection with the Asterias Merger		(3,435)
Tax effect of accumulated other comprehensive income		(732)
NET INCOME/(LOSS)		39,296	(63,698)
Ending balance		161,236	102,455
ASU 2014-09 [Member]
Cumulative-effect adjustment for adoption of Accounting Standard Codification			101
ASU 2016-02 [Member]
Cumulative-effect adjustment for adoption of Accounting Standard Codification		143
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services
Preferred Shares [Member]
Beginning balance
Beginning balance, shares
Cumulative-effect adjustment for adoption of Accounting Standard Codification
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes
Stock-based compensation
Stock-based compensation, shares
Stock-based compensation in subsidiaries
Sale of subsidiary warrants in AgeX
Subsidiary financing transactions with noncontrolling interests - AgeX
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services, shares
Foreign currency translation adjustments
Shares issued in connection with the Asterias Merger
Shares issued in connection with the Asterias Merger, shares
Shares retired in connection with the Asterias Merger
Tax effect of accumulated other comprehensive income
Ending balance
Ending balance, shares
Common Shares [Member]
Beginning balance	$ 354,270	$ 354,270	$ 378,487
Beginning balance, shares	127,136,000	127,136,000	126,866,000
Cumulative-effect adjustment for adoption of Accounting Standard Codification
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes		$ (75)	$ (7)
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes, shares		118,000	3,000
Stock-based compensation		$ 1,361	$ 809
Stock-based compensation, shares
Stock-based compensation in subsidiaries
Sale of subsidiary warrants in AgeX
Subsidiary financing transactions with noncontrolling interests - AgeX			$ (103)
Subsidiary financing transactions with noncontrolling interests - AgeX, shares
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services		$ 79
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services, shares		60,000
Foreign currency translation adjustments
Shares issued in connection with the Asterias Merger		$ 32,353
Shares issued in connection with the Asterias Merger, shares		24,696,000
Shares retired in connection with the Asterias Merger		$ (3,435)
Shares retired in connection with the Asterias Merger, shares		(2,622,000)
Tax effect of accumulated other comprehensive income
NET INCOME/(LOSS)
Ending balance		$ 384,553	$ 379,186
Ending balance, shares		149,388,000	126,869,000
Accumulated Deficit [Member]
Beginning balance	$ (261,856)	$ (261,856)	$ (216,297)
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes
Stock-based compensation
Stock-based compensation in subsidiaries
Sale of subsidiary warrants in AgeX
Subsidiary financing transactions with noncontrolling interests - AgeX
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services
Foreign currency translation adjustments
Shares issued in connection with the Asterias Merger
Shares retired in connection with the Asterias Merger
Tax effect of accumulated other comprehensive income
NET INCOME/(LOSS)		39,310	(63,548)
Ending balance		(222,403)	(279,416)
Accumulated Deficit [Member] | ASU 2016-01 [Member]
Cumulative-effect adjustment for adoption of Accounting Standard Codification			328
Accumulated Deficit [Member] | ASU 2014-09 [Member]
Cumulative-effect adjustment for adoption of Accounting Standard Codification			101
Accumulated Deficit [Member] | ASU 2016-02 [Member]
Cumulative-effect adjustment for adoption of Accounting Standard Codification		143
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services
Noncontrolling Interest/(Deficit) [Member]
Beginning balance	(1,594)	(1,594)	1,622
Cumulative-effect adjustment for adoption of Accounting Standard Codification
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes
Stock-based compensation
Stock-based compensation in subsidiaries			175
Sale of subsidiary warrants in AgeX			737
Subsidiary financing transactions with noncontrolling interests - AgeX			103
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services
Foreign currency translation adjustments
Shares issued in connection with the Asterias Merger
Shares retired in connection with the Asterias Merger
Tax effect of accumulated other comprehensive income
NET INCOME/(LOSS)		(14)	(150)
Ending balance		(1,608)	2,487
Accumulated Other Comprehensive Income/(Loss) [Member]
Beginning balance	$ 1,426	1,426	451
Cumulative-effect adjustment for adoption of Accounting Standard Codification
Shares issued upon vesting of restricted stock units, net of shares retired to pay employees' taxes
Stock-based compensation
Stock-based compensation in subsidiaries
Sale of subsidiary warrants in AgeX
Subsidiary financing transactions with noncontrolling interests - AgeX
Stock-based compensation for shares issued upon vesting of Asterias restricted stock units attributable to post combination services
Foreign currency translation adjustments			75
Shares issued in connection with the Asterias Merger
Shares retired in connection with the Asterias Merger
Tax effect of accumulated other comprehensive income		(732)
NET INCOME/(LOSS)
Ending balance		$ 694	198
Accumulated Other Comprehensive Income/(Loss) [Member] | ASU 2016-01 [Member]
Cumulative-effect adjustment for adoption of Accounting Standard Codification			$ (328)

Stock-Based Awards (Details Nar

Stock-Based Awards (Details Narrative) - $ / shares	Mar. 08, 2019	Feb. 28, 2019	Mar. 31, 2019	Dec. 31, 2017
Asterias Biotherapeutics, Inc. [Member]
Share based compensation, shares			84,940
Asterias Biotherapeutics, Inc. [Member] | RSU Award [Member]
Conversion of shares and common stock issued	60,304
2012 Plan [Member]
Common shares reserved for future issuance				16,000,000
2012 Plan [Member] | Employees and New Chief Financial Officer [Member]
Stock options granted to purchase common stock		1,700,000
2012 Plan [Member] | Employees and New Chief Financial Officer [Member] | Minimum [Member]
Exercise price of options		$ 1.08
2012 Plan [Member] | Employees and New Chief Financial Officer [Member] | Maximum [Member]
Exercise price of options		$ 1.14
Asterias 2013 Equity Incentive Plan [Member]
Number of shares available for grant			7,309,184
Asterias 2013 Equity Incentive Plan [Member] | Asterias Biotherapeutics, Inc. [Member]
Number of shares available for grant			5,189,520

Stock-Based Awards - Schedule o

Stock-Based Awards - Schedule of Share-based Compensation, Employee Stock Purchase Plan, Activity (Details) - $ / shares	1 Months Ended	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2019
Stock Option Plan of 2012 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, Beginning balance		1,885,000
Shares Available for Grant, AgeX distribution adjustment		117,000
Shares Available for Grant, Restricted stock units vested
Shares Available for Grant, Options granted		(1,788,000)
Shares Available for Grant, Options exercised
Shares Available for Grant, Options forfeited/cancelled		769,000
Shares Available for Grant, Ending balance	983,000	983,000
Number of Options Outstanding, Beginning balance		13,867,000
Number of Options Outstanding, AgeX distribution adjustment		(2,000)
Number of Options Outstanding, Restricted stock units vested
Number of Options Outstanding, Options granted		1,788,000
Number of Options Outstanding, Options exercised
Number of Options Outstanding, Options forfeited/cancelled		(769,000)
Number of Options Outstanding, Ending balance	14,884,000	14,884,000
Number of Options Outstanding, Options exercisable	8,927,000	8,927,000
Number of RSUs Outstanding, Beginning balance		402,000
Number of RSUs Outstanding, AgeX distribution adjustment		3,000
Number of RSUs Outstanding, Restricted stock units vested		(129,000)
Number of RSUs Outstanding, Options granted
Number of RSUs Outstanding, Options exercised
Number of RSUs Outstanding, Options forfeited/cancelled
Number of RSUs Outstanding, End balance	276,000	276,000
Weighted Average Exercise Price of Options Outstanding, beginning balance		$ 2.44
Weighted Average Exercise Price of Options, AgeX distribution adjustment
Weighted Average Exercise Price of Options, Restricted stock units vested
Weighted Average Exercise Price of Options, Options granted		1.14
Weighted Average Exercise Price of Options, Options exercised
Weighted Average Exercise Price of Options, Options forfeited/cancelled		1.92
Weighted Average Exercise Price of Options, Outstanding end balance	$ 2.81	2.81
Weighted Average Exercise Price of Options, Options exercisable	$ 3.21	$ 3.21
Asterias 2013 Equity Incentive Plan [Member] | Asterias Biotherapeutics, Inc. [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Available for Grant, Beginning balance	5,190,000
Shares Available for Grant, Options granted	(490,000)
Shares Available for Grant, Options exercised
Shares Available for Grant, Options forfeited/cancelled
Shares Available for Grant, Ending balance	4,700,000	4,700,000
Number of Options Outstanding, Beginning balance
Number of Options Outstanding, Options granted	490,000
Number of Options Outstanding, Options exercised
Number of Options Outstanding, Options forfeited/cancelled
Number of Options Outstanding, Ending balance	490,000	490,000
Number of Options Outstanding, Options exercisable
Number of RSUs Outstanding, Options granted
Number of RSUs Outstanding, Options exercised
Number of RSUs Outstanding, Options forfeited/cancelled
Weighted Average Exercise Price of Options Outstanding, beginning balance
Weighted Average Exercise Price of Options, Options granted	1.59
Weighted Average Exercise Price of Options, Options exercised
Weighted Average Exercise Price of Options, Options forfeited/cancelled
Weighted Average Exercise Price of Options, Outstanding end balance	1.59	$ 1.59
Weighted Average Exercise Price of Options, Options exercisable

Stock-Based Awards - Schedule_2

Stock-Based Awards - Schedule of Weighted Average Assumptions to Calculate Fair Value of Stock Options (Details) - 2012 Plan [Member]	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	6 years 15 days	5 years 10 months 14 days
Risk-free interest rates	2.50%	2.60%
Volatility	64.00%	56.10%
Dividend yield	0.00%	0.00%

Stock-Based Awards - Schedule_3

Stock-Based Awards - Schedule of Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,440	$ 984
Research and Development Expenses [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	122	193
General and Administrative [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock-based compensation expense	$ 1,318	$ 791

Income Taxes (Details Narrative

Income Taxes (Details Narrative) - USD ($)	Nov. 28, 2018	Mar. 23, 2018	Mar. 31, 2018	Mar. 31, 2019
Valuation allowance				$ 4,400,000
AgeX Therapeutics, Inc. [Member]
Proceeds from issuance of common stock		$ 3,200,000
Gain on sale of equity method investment		3,200,000	$ 3,200,000
Taxable gain	$ 26,400,000	2,200,000
Juvenescence Limited [Member]
Taxable gain		$ 29,400,000
Asterias Biotherapeutics, Inc. [Member]
Deferred tax liability				$ 13,000,000

Supplemental Cash Flow Inform_3

Supplemental Cash Flow Information - Schedule of Condensed Consolidated Statements of Cash Flows (Details) - Asterias Biotherapeutics, Inc. [Member] - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Issuance of common stock for the Asterias Merger	$ 32,353
Assumption of liabilities in the Asterias Merger	1,136
Assumptions of warrants in the Asterias Merger	$ 867

Commitments and Contingencies_2

Commitments and Contingencies (Details Narrative)	Jan. 28, 2019USD ($)	Jan. 28, 2019ILS (₪)	Jan. 05, 2019USD ($)	Jan. 28, 2018ILS (₪)ft²m²	Jan. 31, 2019USD ($)	Dec. 31, 2015ft²Subsidiary	Mar. 31, 2019USD ($)ft²m²	Dec. 31, 2018USD ($)	Mar. 31, 2019ILS (₪)ft²m²	Feb. 02, 2019USD ($)	Jan. 24, 2019USD ($)
Operating Leased Assets [Line Items]
Leasehold improvement construction in progress								$ 1,268,000
Cash fee							725,000	391,000
Amortized upfront payment fee							600,000
Access fees							1,250,000
Minimum [Member]
Operating Leased Assets [Line Items]
Minimum annual maintenance fees							135,000
Maximum [Member]
Operating Leased Assets [Line Items]
Minimum annual maintenance fees							150,000
Research and Option Agreement [Member] | Orbit Biomedical Limited [Member]
Operating Leased Assets [Line Items]
Access fees payable			$ 2,500,000		$ 1,250,000
Collaborative research activities description			The access fees payable by BioTime to Orbit for its technology and the injection device are $2.5 million in the aggregate, of which $1.25 million was paid in January 2019 upon execution of the Orbit Agreement and the remaining $1.25 million payment is due on the earlier of (i) six months from the Orbit Agreement date or, (ii) upon completion of certain collaborative research activities using the Orbit technology for the OpRegen Phase I/IIa clinical trial, as specified in the Orbit Agreement. In addition to the access fees, BioTime will pay Orbit for costs of consumables, training services, travel costs and other out of pocket expenses incurred by Orbit for performing services under the Orbit Agreement. BioTime has exclusive rights to the Orbit technology and its injection device for the treatment of dry-AMD during the term of the Orbit Agreement and may extend the term for an additional three months by paying Orbit a cash fee of $500,000.
Cash fee			$ 500,000
Due on Earlier [Member] | Research and Option Agreement [Member] | Orbit Biomedical Limited [Member]
Operating Leased Assets [Line Items]
Access fees payable			$ 1,250,000
Cell Cure [Member]
Operating Leased Assets [Line Items]
Leased area | m²				934
Area of land | ft²				10,054
Base rent and construction allowance per month	$ 26,000
Cell Cure [Member] | NIS [Member]
Operating Leased Assets [Line Items]
Base rent and construction allowance per month | ₪		₪ 93,827
Office Space in New York City [Member]
Operating Leased Assets [Line Items]
Base rent							$ 5,050
Area of land | ft²							900		900
Alameda Lease [Member]
Operating Leased Assets [Line Items]
Leased area | ft²						30,795
Number of buildings for lease | Subsidiary						2
Lease commencement date						Feb. 1, 2016
Lease expiration date						Jan. 31, 2023
Number of years lease can be extended						5 years
Base rent										$ 70,521
Base rent increase rate										3.00%
Security deposit							$ 78,000			$ 424,000
Security deposit reduction in value											$ 78,000
Office and Laboratory Space, Jerusalem, Israel [Member]
Operating Leased Assets [Line Items]
Base rent							$ 11,000
Office and Laboratory Space, Jerusalem, Israel [Member] | April 1, 2018 [Member]
Operating Leased Assets [Line Items]
Construction allowances of leasehold improvements								1,100,000
Office and Laboratory Space, Jerusalem, Israel [Member] | NIS [Member]
Operating Leased Assets [Line Items]
Base rent | ₪									₪ 37,882
Office and Laboratory Space, Jerusalem, Israel [Member] | NIS [Member] | April 1, 2018 [Member]
Operating Leased Assets [Line Items]
Construction allowances of leasehold improvements | ₪				₪ 4,000,000
Office and Laboratory Space, Jerusalem, Israel [Member] | Cell Cure [Member]
Operating Leased Assets [Line Items]
Leased area | m²							728.5		728.5
Number of years lease can be extended				5 years			5 years
Area of land | ft²							7,842		7,842
Lease expiration				A lease that expires on December 31, 2025			A lease that expires December 31, 2020
January 2018 Lease [Member]
Operating Leased Assets [Line Items]
Leasehold improvement construction in progress								1,100,000
Deposit								$ 388,000

Commitments and Contingencies -

Commitments and Contingencies - Schedule of Supplemental Cash Flow Information Related to Leases (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2019USD ($)
Commitments and Contingencies Disclosure [Abstract]
Operating cash flows from operating leases	$ 331
Operating cash flows from financing leases	7
Financing cash flows from financing leases	$ 6

Commitments and Contingencies_3

Commitments and Contingencies - Schedule of Supplemental Balance Sheet Information Related to Leases (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 02, 2019	Dec. 31, 2018
Commitments and Contingencies Disclosure [Abstract]
Right-of-use assets, net	$ 4,678
Right-of-use lease liabilities, current	923
Right-of-use lease liabilities, noncurrent	4,016		$ 1,854
Total operating lease liabilities	4,939	$ 2,000
Property and equipment, gross	146
Accumulated depreciation	(28)
Property and equipment, net	118
Current liabilities	954		237
Long-term liabilities	103		$ 104
Total finance lease liabilities	$ 134
Weighted average remaining lease term Operating leases	4 years 10 months 25 days
Weighted average remaining lease term Finance leases	4 years 2 months 12 days
Weighted average discount rate Operating leases	9.10%
Weighted average discount rate Finance leases	10.00%

Commitments and Contingencies_4

Commitments and Contingencies - Schedule of Future Minimum Lease Commitments (Details) - USD ($) $ in Thousands	Mar. 31, 2019	Jan. 02, 2019
Commitments and Contingencies Disclosure [Abstract]
2019	$ 994
2020	1,339
2021	1,245
2022	1,251
2023	393
Thereafter	1,015
Total lease payments	6,237
Less imputed interest	(1,298)
Total	4,939	$ 2,000
2019	33
2020	43
2021	36
2022	36
2023	15
Thereafter
Total lease payments	163
Less imputed interest	(29)
Total	$ 134